Solid forms of CDK2 inhibitors
Patent Information
- Application Number
- JP2023537491
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-12-24
- Filing Date
- 2021-12-21
- Publication Date
- 2024-11-28
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing forms of the CDK2 inhibitor PF-07104091 lack desirable properties such as high crystallinity, purity, low hygroscopicity, favorable dissolution, mechanical stability, and manufacturability, which are essential for effective pharmaceutical applications.
The development of crystalline forms (Form 2 and Form 3) and amorphous form (Form 4) of PF-07104091, characterized by specific PXRD, Raman, and 13C NMR patterns, providing improved crystallinity, purity, and stability.
The new solid forms exhibit enhanced properties, including high purity, low hygroscopicity, and improved manufacturability, facilitating their use in pharmaceutical compositions for cancer treatment.
Smart Images

Figure 00000000_0001_ABST 
Figure 00000000_0000_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to solid forms of (1R,3S)-3-[3-({[3-(methoxymethyl)-1-methyl-1H-pyrazol-5-yl]carbonyl}amino)-1H-pyrazol-5-yl]cyclopentylpropan-2-ylcarbamate (also referred to herein as PF-07104091), pharmaceutical compositions comprising such solid forms, and methods of using such solid forms and pharmaceutical compositions for the treatment of cancer. [Background technology]
[0002] The compound (1R,3S)-3-[3-({[3-(methoxymethyl)-1-methyl-1H-pyrazol-5-yl]carbonyl}amino)-1H-pyrazol-5-yl]cyclopentylpropan-2-ylcarbamate (PF-07104091) has the structure:
[0003] [ka] It is a potent inhibitor of cyclin-dependent kinase 2 (CDK2) with
[0004] The preparation of PF-07104091 isolated as a crystalline monohydrate (Form 1) is disclosed in International Patent Publication No. WO2020 / 157652 and in U.S. Pat. No. 11,014,911, the contents of each of which are incorporated by reference in their entireties. Summary of the Invention [Problem to be solved by the invention]
[0005] The present invention provides crystalline forms of PF-07104091 that have desirable properties such as high crystallinity, high purity, low hygroscopicity, favorable dissolution or mechanical properties, improved manufacturability or filterability, and / or favorable stability. The present invention also provides amorphous PF-07104091. [Means for solving the problem]
[0006] The present invention provides a solid form of (1R,3S)-3-[3-({[3-(methoxymethyl)-1-methyl-1H-pyrazol-5-yl]carbonyl}amino)-1H-pyrazol-5-yl]cyclopentylpropan-2-ylcarbamate (PF-07104091).
[0007] In some aspects and embodiments, the present invention provides a crystalline form of PF-07104091. In some aspects and embodiments, the crystalline form is anhydrous crystalline PF-07104091 (Form 2). In preferred aspects and embodiments, the crystalline form is crystalline PF-07104091 monohydrate (Form 3). In other aspects and embodiments, the crystalline form is anhydrous crystalline PF-07104091 (Form 5).
[0008] In other aspects and embodiments, the present invention provides an amorphous form of PF-07104091. In some aspects and embodiments, the amorphous form is amorphous PF-07104091 (Form 4).
[0009] In one aspect, the present invention provides a method for producing a method for treating a cancer cell comprising: (1) a powder X-ray diffraction (PXRD) pattern (2θ) comprising: (a) one, two, three, four, five, or more than five peaks selected from the group consisting of peaks at °2θ±0.2°2θ in Table 1; or (b) peaks at essentially the same 2θ values as in Figure 2; (2)(a) cm in Table 2 -1 ±2cm -1 One, two, three, four, five or more wave numbers (cm -1 ) values, or (b) essentially the same wavenumbers (cm -1 ) values, or (3) (a) one, two, three, four, five, or more than five resonance (ppm) values selected from the group consisting of values in Table 3 at ppm ± 0.2 ppm; or (b) essentially the same resonance (ppm) values as in FIG. 13C solid-state NMR spectrum (ppm), or any combination of two or more of (1)(a)-(b), (2)(a)-(b), and (3)(a)-(b), provided that they are not mutually exclusive; Anhydrous crystalline PF-07104091 (Form 2) is provided.
[0010] In a further aspect, the present invention provides a method for producing a method for treating a cancer cell comprising the steps of: (a) a powder X-ray diffraction (PXRD) pattern containing peaks at 2θ values of 9.8, 13.3, and 17.4°2θ±0.2°2θ; (b) 1691, 1582 and 996 cm -1 ±2cm -1 Wave number (cm -1 ) values, or (c) Includes resonance (ppm) values of 24.1, 39.8 and 41.6 ppm ± 0.2 ppm 13 C solid-state NMR spectrum, or any combination of two or more of (a), (b) and (c).
[0023] The present invention provides anhydrous crystalline PF-07104091 (Form 2), having the formula:
[0011] In some embodiments, the crystalline form is substantially pure anhydrous crystalline PF-07104091 (Form 2).
[0012] In another aspect, the present invention provides a pharmaceutical composition comprising anhydrous crystalline PF-07104091 (Form 2) according to any aspect or embodiment described herein and a pharma- ceutically acceptable carrier or excipient.
[0013] In one aspect, the present invention provides a method for producing a method for treating a cancer cell comprising: (1) a powder X-ray diffraction (PXRD) pattern (2θ) comprising: (a) one, two, three, four, five, or more than five peaks selected from the group consisting of peaks at °2θ±0.2 °2θ in Table 4; or (b) peaks at essentially the same 2θ values as in Figure 3; (2)(a) cm in Table 5 -1 ±2cm -1One, two, three, four, five or more wave numbers (cm -1 ) values, or (b) essentially the same wavenumbers (cm -1 ) values, or (3) (a) one, two, three, four, five, or more than five resonance (ppm) values selected from the group consisting of values in Table 6 at ppm ± 0.2 ppm; or (b) essentially the same resonance (ppm) values as in FIG. 13 C solid-state NMR spectrum (ppm), or any combination of two or more of (1)(a)-(b), (2)(a)-(b), and (3)(a)-(b), provided that they are not mutually exclusive; Crystalline PF-07104091 monohydrate (Form 3) is provided.
[0014] In a further aspect, the present invention provides a method for producing a method for treating a cancer cell comprising the steps of: (a) a powder X-ray diffraction (PXRD) pattern containing peaks at 2θ values of 8.4, 10.1, and 21.5°2θ±0.2°2θ; (b) 1657, 1595 and 1408 cm -1 ±2cm -1 Wave number (cm -1 ) values, or (c) Includes resonance (ppm) values of 25.2, 37.5 and 159.3 ppm ± 0.2 ppm 13 C solid-state NMR spectrum, or any combination of two or more of (a), (b) and (c). The present invention provides crystalline PF-07104091 monohydrate (Form 3) having the formula:
[0015] In some embodiments, the crystalline form is substantially pure crystalline PF-07104091 monohydrate (Form 3).
[0016] In another aspect, the present invention provides a pharmaceutical composition comprising crystalline PF-07104091 monohydrate (Form 3) according to any aspect or embodiment described herein and a pharma- ceutically acceptable carrier or excipient. [Brief description of the drawings]
[0017] [Figure 1] FIG. 1 shows the PXRD pattern of PF-07104091 monohydrate (Form 1). [Diagram 2] FIG. 1 shows the PXRD pattern of PF-07104091 (Form 2). [Diagram 3] FIG. 1 shows the PXRD pattern of PF-07104091 monohydrate (Form 3). [Figure 4] FIG. 1 shows the PXRD pattern of PF-07104091 (Form 4). [Diagram 5] FIG. 1 shows the PXRD pattern of PF-07104091 (Form 5). [Figure 6] FIG. 1 shows the FT-Raman spectrum of PF-07104091 monohydrate (Form 1). [Figure 7] FIG. 1 shows the FT-Raman spectrum of PF-07104091 (Form 2). [Figure 8] FIG. 1 shows the FT-Raman spectrum of PF-07104091 monohydrate (Form 3). [Figure 9] FIG. 1 shows the FT-Raman spectrum of PF-07104091 (Form 5). [Figure 10] FIG. 1 shows the carbon CPMAS spectrum of PF-07104091 monohydrate (Form 1) (# indicates spinning sidebands). [Figure 11] FIG. 1 shows the carbon CPMAS spectrum of PF-07104091 (Form 2) (# indicates spinning sidebands). [Figure 12] FIG. 1 shows the carbon CPMAS spectrum of PF-07104091 monohydrate (Form 3) (# indicates spinning sidebands). [Figure 13]FIG. 1 shows the carbon CPMAS spectrum of PF-07104091 (Form 5) (# indicates spinning sidebands). [Figure 14] FIG. 1 shows a differential scanning calorimetry thermogram of PF-07104091 (Form 4) at a ramp rate of 10° C. / min. [Figure 15] FIG. 1 shows a thermogravimetric analysis of PF-07104091 (Form 5). [Figure 16] FIG. 1 shows the single crystal structure of PF-07104091 monohydrate (Form 3). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0018] The present invention can be more easily understood by referring to the following detailed description of the embodiments of the present invention and the examples contained herein. It should be understood that the terms used herein are only for the purpose of describing specific embodiments and are not intended to be limiting. It should be further understood that, unless specifically defined herein, the terms used herein are given their customary meaning as known in the relevant technical field.
[0019] As used herein, the singular forms "a," "an," and "the" include plural references unless otherwise indicated. For example, "a" substituent includes one or more substituents.
[0020] The term "about" means having a value that falls within an acceptable standard error as considered by one of ordinary skill in the art.
[0021] The term "amorphous," as used herein, refers to a solid material that (1) lacks order in three dimensions, or (2) exhibits order in less than three dimensions, only short-range (e.g., less than 10 Å) order, or both. Amorphous solids typically give scattered PXRD patterns that include one or two broad peaks.
[0022] The term "anhydrous," as used herein, refers to a crystalline form that contains only the active pharmaceutical ingredient (API) as part of its crystal lattice.
[0023] The term "crystalline" as used herein means having a regularly repeating arrangement of molecules or external planes. Crystalline forms may differ with respect to thermodynamic stability, physical parameters, x-ray structure and preparation process.
[0024] The terms "polymorph" or "polymorphism" refer to a crystalline form of a compound with a distinct spatial lattice arrangement compared to other crystalline forms of the same compound.
[0025] The term "solvate" describes a molecular complex that contains a compound (e.g., the active pharmaceutical ingredient (API) of a drug product) and one or more solvent molecules (e.g., water or ethanol) in stoichiometric or non-stoichiometric amounts. If the solvent is tightly bound to the compound, the resulting complex will have a well-defined stoichiometry that is independent of humidity. However, if the solvent is weakly bound, such as in channel solvates and hygroscopic compounds, the solvent content will depend on humidity and drying conditions. In such cases, the complex will often be non-stoichiometric.
[0026] The term "hydrate" describes a solvate containing a compound and a stoichiometric or non-stoichiometric amount of water. A "monohydrate" is a hydrate containing one molecule of water per molecule of compound (i.e., a 1:1 stoichiometry of water to compound).
[0027] The phrase "substantially pure" means that the crystalline or amorphous form described as being substantially pure contains less than 5% by weight, preferably less than 3% by weight, and more preferably less than 1% by weight of impurities, including any other physical forms of the compound (i.e., greater than 95%, preferably greater than 97% and more preferably greater than 99% chemical purity).
[0028] As used herein, the term "essentially the same" means that typical variability for a particular method is taken into account. For example, with respect to X-ray diffraction peak positions, the term "essentially the same" means that typical variability in peak positions and intensities is taken into account. Those skilled in the art will recognize that peak positions (2θ) will exhibit some variability, typically on the order of ±0.2°. Furthermore, those skilled in the art will recognize that relative peak intensities will exhibit instrument-to-instrument variability, as well as variability due to crystallinity, preferred orientation, prepared sample surface, and other factors known to those skilled in the art, and should be interpreted as merely a qualitative measurement. Similarly, Raman spectrum wavenumbers (cm -1 ) values are typically ±2cm -1 shows a degree of variability, while 13 C solid-state NMR spectra (ppm) typically exhibit variability on the order of ±0.2 ppm.
[0029] The inventions described herein may suitably be practiced in the absence of any element not specifically disclosed herein. Thus, for example, in each instance herein, any of the terms "comprising," "consisting essentially of," and "consisting of" may be replaced with either of the other two terms.
[0030] The solid forms of PF-07104091 described herein can be characterized by the following methods: (1) powder X-ray diffraction (PXRD) (2θ); (2) Raman spectroscopy (cm -1 ), (3) 13 C solid-state NMR spectroscopy (ppm) or (4) differential scanning calorimetry (DSC) (Tg °C), or any combination of two or more of methods (1), (2), (3), and (4).
[0031] In each of the aspects and embodiments herein characterized by PXRD, the PXRD peaks were measured using CuKα radiation at 1.5418λ.
[0032] Such solid forms may be further characterized by additional techniques such as Fourier transform infrared spectroscopy (FTIR), thermogravimetric analysis (TGA) or differential thermal analysis (DTA).
[0033] Comparative PXRD, Raman and NMR spectra for crystalline PF-07104091 monohydrate (Form 1) as described in International Patent Publication No. WO2020 / 157652 and in U.S. Pat. No. 11,014,911. 13 C ssNMR data is provided in Figures 1, 6 and 10, respectively.
[0034] In one aspect, the present invention provides anhydrous crystalline PF-07104091 (Form 2).
[0035] In some embodiments, PF-07104091 (Form 2) is characterized by its powder X-ray diffraction (PXRD) pattern. In other embodiments, PF-07104091 (Form 2) is characterized by its Raman spectrum. In other embodiments, PF-07104091 (Form 2) is characterized by its 13 Characterized by C solid-state NMR spectroscopy.
[0036] In further embodiments, anhydrous crystalline PF-07104091 (Form 2) is characterized by any combination of two or more of these methods. Exemplary combinations including two or more of the following are provided herein: powder X-ray diffraction (PXRD) pattern (2θ), Raman spectrum wavenumbers (cm -1 )or 13 C solid-state NMR spectrum (ppm).
[0037] In some embodiments, PF-07104091 (Form 2) is characterized by PXRD and Raman. In other embodiments, PF-07104091 (Form 2) is characterized by PXRD and Raman. 13 In another embodiment, PF-07104091 (Form 2) is characterized by Raman and 13In another embodiment, PF-07104091 (Form 2) is characterized by PXRD, Raman and 13 Characterized by C solid-state NMR.
[0038] In one aspect, the present invention provides anhydrous crystalline PF-07104091 (Form 2), characterized by a powder X-ray diffraction (PXRD) pattern.
[0039] In an embodiment, the invention provides PF-07104091 (Form 2) having a powder X-ray diffraction (PXRD) pattern comprising peaks at 2θ values of 9.8, 13.3, and 17.4 °2θ±0.2 °2θ.
[0040] In one embodiment, the invention provides PF-07104091 (Form 2) having a powder X-ray diffraction (PXRD) pattern comprising peaks at 2θ values of 4.2, 9.8, 13.3, and 17.4 °2θ±0.2 °2θ.
[0041] In an embodiment, the invention provides PF-07104091 (Form 2) having a powder X-ray diffraction (PXRD) pattern comprising peaks at 2θ values of 7.5, 9.8, 13.3, and 17.4 °2θ±0.2 °2θ.
[0042] In another embodiment, the invention provides PF-07104091 (Form 2) having a powder X-ray diffraction (PXRD) pattern comprising peaks at 2θ values of 4.2, 7.5, 9.8, 13.3, and 17.4 °2θ±0.2 °2θ.
[0043] In one embodiment, the invention provides PF-07104091 (Form 2) having a powder X-ray diffraction (PXRD) pattern comprising peaks at 2θ values of 9.8, 13.3, and 17.4 °2θ±0.2 °2θ, and optionally one or two peaks selected from the group consisting of 4.2 and 7.5 °2θ±0.2 °2θ.
[0044] In another embodiment, the invention provides PF-07104091 (Form 2) having a PXRD pattern comprising three or more peaks at values 2θ selected from the group consisting of 4.2, 7.5, 9.8, 13.3, and 17.4 °2θ±0.2 °2θ.
[0045] In another embodiment, the invention provides PF-07104091 (Form 2) having a PXRD pattern including: (a) one, two, three, four, five, or more than five peaks selected from the group consisting of peaks at °2θ±0.2 °2θ in Table 1, or (b) peaks at essentially the same 2θ values as in Figure 2.
[0046] In another aspect, the present invention provides anhydrous crystalline PF-07104091 (Form 2) characterized by Raman spectroscopy.
[0047] In one embodiment, the present invention provides a method for detecting the 1691, 1582 and 996 cm -1 ±2cm -1 Wave number (cm -1 ) values.
[0048] In another embodiment, the present invention provides a method for detecting the 1691, 1582, 1036 and 996 cm -1 ±2cm -1 Wave number (cm -1 ) values.
[0049] In another embodiment, the present invention provides a method for producing a compound having a molecular weight of 1691, 1582, 1365 and 996 cm -1 ±2cm -1 Wave number (cm -1 ) values.
[0050] In another embodiment, the present invention provides the 1691, 1582, 1365, 1036 and 996 cm -1 ±2cm -1 Wave number (cm -1) values.
[0051] In one embodiment, the present invention provides a method for detecting the 1691, 1582 and 996 cm -1 ±2cm -1 Wave number (cm -1 ) values, as well as 1365 and 1036 cm -1 ±2cm -1 and wherein the Raman spectrum comprises one or two peaks selected from the group consisting of:
[0052] In one embodiment, the present invention provides a method for the treatment of a cancer cell comprising administering to a patient a cancer cell comprising: -1 ±2cm -1 One, two, three, four, five or more wave numbers (cm -1 ) values, or (b) essentially the same wavenumbers (cm -1 ) values.
[0053] In another aspect, the present invention provides a method for producing a composition comprising: 13 Provided is anhydrous crystalline PF-07104091 (Form 2) characterized by C solid-state NMR spectroscopy.
[0054] In one embodiment, the present invention includes resonance (ppm) values of 24.1, 39.8 and 41.6 ppm ± 0.2 ppm. 13 Provided is PF-07104091 (Form 2) having a C solid-state NMR spectrum.
[0055] In one embodiment, the present invention includes resonance (ppm) values of 21.8, 24.1, 39.8 and 41.6 ppm ± 0.2 ppm. 13 Provided is PF-07104091 (Form 2) having a C solid-state NMR spectrum.
[0056] In one embodiment, the present invention includes resonance (ppm) values of 24.1, 39.8, 41.6 and 138.2 ppm ± 0.2 ppm.13 Provided is PF-07104091 (Form 2) having a C solid-state NMR spectrum.
[0057] In another embodiment, the present invention includes resonance (ppm) values of 21.8, 24.1, 39.8, 41.6 and 138.2 ppm ± 0.2 ppm. 13 Provided is PF-07104091 (Form 2) having a C solid-state NMR spectrum.
[0058] In one embodiment, the present invention comprises one or two resonance (ppm) values selected from the group consisting of 24.1, 39.8 and 41.6 ppm ± 0.2 ppm, and 21.8 and 138.2 ppm ± 0.2 ppm. 13 Provided is PF-07104091 (Form 2) having a C solid-state NMR spectrum.
[0059] In one embodiment, the present invention provides a composition comprising one or two peaks selected from the group consisting of resonance (ppm) values of 24.1, 39.8 and 41.6 ppm ± 0.2 ppm, and optionally 21.8 and 138.2 ppm ± 0.2 ppm. 13 Provided is PF-07104091 (Form 2) having a C solid-state NMR spectrum.
[0060] In another embodiment, the present invention provides a composition comprising three or more resonance (ppm) values selected from the group consisting of 21.8, 24.1, 39.8, 41.6 and 138.2 ppm ± 0.2 ppm. 13 Provided is PF-07104091 (Form 2) having a C solid-state NMR spectrum.
[0061] In another embodiment, the present invention comprises (a) one, two, three, four, five, or more than five resonance (ppm) values selected from the group consisting of the values in Table 3 in ppm ± 0.2 ppm, or (b) resonance (ppm) values essentially the same as in Figure 11. 13 Provided is PF-07104091 (Form 2) with C solid state NMR spectrum (ppm).
[0062] In another aspect, the present invention provides a method for producing a composition comprising: (a) a powder X-ray diffraction (PXRD) pattern containing peaks at 2θ values of 9.8, 13.3, and 17.4°2θ±0.2°2θ; (b) 1691, 1582 and 996 cm -1 ±2cm -1 Wave number (cm -1 ) values, or (c) Includes resonance (ppm) values of 24.1, 39.8 and 41.6 ppm ± 0.2 ppm 13 C solid-state NMR spectrum, or any combination of two or more of (a), (b) and (c).
[0023] The present invention provides anhydrous crystalline PF-07104091 (Form 2), having the formula:
[0063] In another aspect, the present invention provides a method for producing a composition comprising: (a) a powder X-ray diffraction (PXRD) pattern comprising peaks at 2θ values of 9.8 and 13.3 °2θ ± 0.2 °2θ, and optionally further comprising a peak at a 2θ value of 17.4 °2θ ± 0.2 °2θ; (b) 1691 cm -1 ±2cm -1 Wave number (cm -1 ) values, as well as 1582 and 996 cm -1 ±2cm -1 Wave number (cm -1 ) values, or (c) Includes resonance (ppm) values of 24.1, 39.8 and 41.6 ppm ± 0.2 ppm 13 C solid-state NMR spectrum, or any combination of two or more of (a), (b) and (c).
[0023] The present invention provides anhydrous crystalline PF-07104091 (Form 2), having the formula:
[0064] In another aspect, the present invention provides a method for producing a composition comprising: (1) (a) 9.8, 13.3 and 17.4°2θ ± 0.2°2θ; (b) 4.2, 9.8, 13.3 and 17.4°2θ±0.2°2θ; (c) 7.5, 9.8, 13.3, and 17.4°2θ±0.2°2θ; or (d) 4.2, 7.5, 9.8, 13.3 and 17.4°2θ±0.2°2θ A powder X-ray diffraction (PXRD) pattern including peaks at 2θ values of (2) (a) 1691, 1582 and 996 cm -1 ±2cm -1 , (b) 1691, 1582, 1036 and 996 cm -1 ±2cm -1 , (c) 1691, 1582, 1365 and 996 cm -1 ±2cm -1 ,or (d) 1691, 1582, 1365, 1036 and 996 cm -1 ±2cm -1 Wave number (cm -1 ) values, or (3) (a) 24.1, 39.8 and 41.6 ppm ± 0.2 ppm; (b) 21.8, 24.1, 39.8 and 41.6 ppm ± 0.2 ppm; (c) 24.1, 39.8, 41.6 and 138.2 ppm ± 0.2 ppm; or (d) 21.8, 24.1, 39.8, 41.6 and 138.2 ppm ± 0.2 ppm Includes resonance (ppm) values 13 C solid-state NMR spectrum, or any combination of two or more of (1)(a)-(d), (2)(a)-(d), and (3)(a)-(d).
[0023] The present invention provides anhydrous crystalline PF-07104091 (Form 2), having the formula:
[0065] In some embodiments of each of the aspects and embodiments of PF-07104091 (Form 2) herein, the crystalline form is substantially pure anhydrous crystalline PF-07104091 (Form 2).
[0066] In another aspect, the present invention provides a pharmaceutical composition comprising anhydrous crystalline PF-07104091 (Form 2) according to any aspect or embodiment described herein and a pharma- ceutically acceptable carrier or excipient.
[0067] In another aspect, the invention provides a method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of anhydrous crystalline PF-07104091 (Form 2), or a pharmaceutical composition comprising anhydrous crystalline PF-07104091 (Form 2), according to any aspect or embodiment described herein.
[0068] In another aspect, the invention provides a method of treating cancer in a subject in need thereof, comprising administering to the subject an amount of anhydrous crystalline PF-07104091 (Form 2) according to any aspect or embodiment described herein, or a pharmaceutical composition comprising anhydrous crystalline PF-07104091 (Form 2), and an amount of an additional anti-cancer agent, wherein the amounts of PF-07104091 (Form 2) and the additional anti-cancer agent together are effective to treat cancer.
[0069] In another aspect, the present invention provides anhydrous crystalline PF-07104091 (Form 2) according to any aspect or embodiment described herein, or a pharmaceutical composition comprising anhydrous crystalline PF-07104091 (Form 2), for use in the treatment of cancer.
[0070] In another aspect, the invention provides anhydrous crystalline PF-07104091 (Form 2), according to any aspect or embodiment described herein, for use in the manufacture of a medicament for the treatment of cancer.
[0071] In another aspect, the present invention provides a use of anhydrous crystalline PF-07104091 (Form 2), or a pharmaceutical composition comprising anhydrous crystalline PF-07104091 (Form 2), according to any aspect or embodiment described herein, for the treatment of cancer.
[0072] In another aspect, the present invention provides the use of anhydrous crystalline PF-07104091 (Form 2), according to any aspect or embodiment described herein, in the manufacture of a medicament for the treatment of cancer.
[0073] In each of the aspects and embodiments of anhydrous crystalline PF-07104091 (Form 2) described herein, the crystalline form may be substantially pure anhydrous crystalline PF-07104091 (Form 2).
[0074] Each of the embodiments described herein for anhydrous crystalline PF-07104091 (Form 2) may be combined with other such embodiments, provided that the embodiments are not mutually exclusive.
[0075] In a preferred embodiment, the present invention provides crystalline PF-07104091 monohydrate (Form 3). In some embodiments, the crystalline PF-07104091 monohydrate (Form 3) is characterized by its powder X-ray diffraction (PXRD) pattern. In other embodiments, the crystalline PF-07104091 monohydrate (Form 3) is characterized by its Raman spectrum. In other embodiments, the crystalline PF-07104091 monohydrate (Form 3) is characterized by its 13 Characterized by C solid-state NMR spectroscopy.
[0076] In further embodiments, the crystalline PF-07104091 monohydrate (Form 3) is characterized by any combination of two or more of these methods. Exemplary combinations including two or more of the following are provided herein: Powder X-ray Diffraction (PXRD) pattern (2θ), Raman Spectral Wavenumbers (cm -1 )or 13C solid state NMR spectrum (ppm). In some embodiments, the crystalline PF-07104091 monohydrate (Form 3) is characterized by PXRD and Raman. In other embodiments, the crystalline PF-07104091 monohydrate (Form 3) is characterized by PXRD and Raman. 13 In another embodiment, the crystalline PF-07104091 monohydrate (Form 3) is characterized by Raman and 13 In another embodiment, the crystalline PF-07104091 monohydrate (Form 3) is characterized by PXRD, Raman and 13 Characterized by C solid-state NMR.
[0077] In one aspect, the present invention provides crystalline PF-07104091 monohydrate (Form 3), characterized by a powder X-ray diffraction (PXRD) pattern.
[0078] In one embodiment, the invention provides crystalline PF-07104091 monohydrate (Form 3) having a powder X-ray diffraction (PXRD) pattern comprising peaks at 2θ values of 8.4, 10.1, and 21.5 °2θ±0.2 °2θ.
[0079] In one embodiment, the invention provides crystalline PF-07104091 monohydrate (Form 3) having a powder X-ray diffraction (PXRD) pattern comprising peaks at 2θ values of 8.4, 10.1, 16.9, and 21.5 °2θ±0.2 °2θ.
[0080] In one embodiment, the invention provides crystalline PF-07104091 monohydrate (Form 3) having a powder X-ray diffraction (PXRD) pattern comprising peaks at 2θ values of 8.4, 10.1, 21.5, and 27.0 °2θ±0.2 °2θ.
[0081] In another embodiment, the invention provides crystalline PF-07104091 monohydrate (Form 3) having a powder X-ray diffraction (PXRD) pattern comprising peaks at 2θ values of 8.4, 10.1, 16.9, 21.5, and 27.0 °2θ±0.2 °2θ.
[0082] In another embodiment, the present invention provides (a) 8.4, 10.1 and 21.5°2θ±0.2°2θ; (b) 8.4, 10.1, 16.9 and 21.5°2θ±0.2°2θ; (c) 8.4, 10.1, 21.5 and 27.0°2θ ± 0.2°2θ, or (d) 8.4, 10.1, 16.9, 21.5 and 27.0°2θ±0.2°2θ The present invention provides crystalline PF-07104091 monohydrate (Form 3) having a powder X-ray diffraction (PXRD) pattern including peaks at 2θ values of:
[0083] In one embodiment, the invention provides crystalline PF-07104091 monohydrate (Form 3) having a powder X-ray diffraction (PXRD) pattern comprising peaks at 2θ values of 8.4, 10.1, and 21.5 °2θ±0.2 °2θ, and optionally one or two peaks selected from the group consisting of 16.9 and 27.0 °2θ±0.2 °2θ.
[0084] In another embodiment, the present invention provides crystalline PF-07104091 monohydrate (Form 3) having a PXRD pattern comprising three or more peaks at 2θ values selected from the group consisting of 8.4, 10.1, 16.9, 21.5, and 27.0 °2θ±0.2 °2θ.
[0085] In another embodiment, the present invention provides crystalline PF-07104091 monohydrate (Form 3) having a PXRD pattern including: (a) one, two, three, four, five, or more than five peaks selected from the group consisting of peaks at °2θ±0.2 °2θ in Table 4, or (b) peaks at essentially the same 2θ values as in Figure 3.
[0086] In another aspect, the present invention provides crystalline PF-07104091 monohydrate (Form 3) characterized by Raman spectroscopy.
[0087] In one embodiment, the present invention provides a method for detecting the 1657, 1595 and 1408 cm -1 ±2cm -1 Wave number (cm -1 ) values.
[0088] In another embodiment, the present invention provides a method for producing a compound having a molecular weight of 1657, 1595, 1408 and 923 cm -1 ±2cm -1 Wave number (cm -1 ) values.
[0089] In another embodiment, the present invention provides a method for producing a compound having a molecular weight of 1657, 1595, 1408 and 1272 cm -1 ±2cm -1 Wave number (cm -1 ) values.
[0090] In another embodiment, the present invention provides a method for producing a 1657, 1595, 1408, 1272 and 923 cm -1 ±2cm -1 Wave number (cm -1 ) values.
[0091] In another embodiment, the present invention provides (a) 1657, 1595 and 1408 cm -1 ±2cm -1 , (b) 1657, 1595, 1408 and 923 cm -1 ±2cm -1 , (c) 1657, 1595, 1408 and 1272 cm -1 ±2cm -1 ,or (d) 1657, 1595, 1408, 1272 and 923 cm -1 ±2cm -1 Wave number (cm-1 ) values.
[0092] In one embodiment, the present invention provides a method for detecting the 1657, 1595 and 1408 cm -1 ±2cm -1 Wave number (cm -1 ) values, as well as 1272 and 923 cm -1 ±2cm -1 The present invention provides a crystalline PF-07104091 monohydrate (Form 3) having a Raman spectrum comprising one or two peaks selected from the group consisting of:
[0093] In one embodiment, the present invention provides a method for the preparation of a compound according to the present invention, comprising: -1 ±2cm -1 One, two, three, four, five or more wave numbers (cm -1 ) values, or (b) essentially the same wavenumbers (cm -1 ) values.
[0094] In another aspect, the present invention provides a method for producing a composition comprising: 13 To provide crystalline PF-07104091 monohydrate (Form 3) characterized by C solid-state NMR spectroscopy.
[0095] In one embodiment, the present invention includes resonance (ppm) values of 25.2 and 37.5 ppm ± 0.2 ppm. 13 To provide crystalline PF-07104091 monohydrate (Form 3) having a C solid-state NMR spectrum.
[0096] In one embodiment, the present invention includes resonance (ppm) values of 25.2, 37.5 and 159.3 ppm ± 0.2 ppm. 13 To provide crystalline PF-07104091 monohydrate (Form 3) having a C solid-state NMR spectrum.
[0097] In one embodiment, the present invention includes resonance (ppm) values of 25.2, 37.5, 151.9 and 159.3 ppm ± 0.2 ppm. 13 To provide crystalline PF-07104091 monohydrate (Form 3) having a C solid-state NMR spectrum.
[0098] In one embodiment, the present invention includes resonance (ppm) values of 25.2, 37.5, 152.5 and 159.3 ppm ± 0.2 ppm. 13 To provide crystalline PF-07104091 monohydrate (Form 3) having a C solid-state NMR spectrum.
[0099] In another embodiment, the present invention includes resonance (ppm) values of 25.2, 37.5, 151.9, 152.5 and 159.3 ppm ± 0.2 ppm. 13 To provide crystalline PF-07104091 monohydrate (Form 3) having a C solid-state NMR spectrum.
[0100] In one embodiment, the present invention comprises one or two resonance (ppm) values selected from the group consisting of 25.2, 37.5 and 159.3 ppm ± 0.2 ppm, and 151.9 and 152.5 ppm ± 0.2 ppm. 13 To provide crystalline PF-07104091 monohydrate (Form 3) having a C solid-state NMR spectrum.
[0101] In another embodiment, the present invention provides (a) 25.2 and 37.5 ppm ± 0.2 ppm; (b) 25.2, 37.5 and 159.3 ppm ± 0.2 ppm; (c) 25.2, 37.5, 151.9 and 159.3 ppm ± 0.2 ppm; (d) 25.2, 37.5, 152.5 and 159.3 ppm ± 0.2 ppm; or (e) 25.2, 37.5, 151.9, 152.5 and 159.3 ppm ± 0.2 ppm Includes resonance (ppm) values 13To provide crystalline PF-07104091 monohydrate (Form 3) having a C solid-state NMR spectrum.
[0102] In one embodiment, the present invention provides a method for producing a composition comprising the steps of: a) providing a composition comprising one or two peaks selected from the group consisting of resonance (ppm) values of 25.2, 37.5 and 159.3 ppm ± 0.2 ppm, and optionally 151.9 and 152.5 ppm ± 0.2 ppm. 13 To provide crystalline PF-07104091 monohydrate (Form 3) having a C solid-state NMR spectrum.
[0103] In another embodiment, the present invention provides a composition comprising three or more resonance (ppm) values selected from the group consisting of 25.2, 37.5, 151.9, 152.5 and 159.3 ppm ± 0.2 ppm. 13 To provide crystalline PF-07104091 monohydrate (Form 3) having a C solid-state NMR spectrum.
[0104] In another embodiment, the present invention comprises (a) one, two, three, four, five or more than five resonance (ppm) values selected from the group consisting of the values in Table 6 in ppm ± 0.2 ppm, or (b) resonance (ppm) values essentially the same as in Figure 12. 13 Provided is crystalline PF-07104091 monohydrate (Form 3) with C solid-state NMR spectrum (ppm).
[0105] In another aspect, the present invention provides a method for producing a composition comprising: (a) a powder X-ray diffraction (PXRD) pattern containing peaks at 2θ values of 8.4, 10.1, and 21.5°2θ±0.2°2θ; (b) 1657, 1595 and 1408 cm -1 ±2cm -1 Wave number (cm -1 ) values, or (c) Includes resonance (ppm) values of 25.2, 37.5 and 159.3 ppm ± 0.2 ppm 13 C solid-state NMR spectrum, or any combination of two or more of (a), (b) and (c). The present invention provides crystalline PF-07104091 monohydrate (Form 3) having the formula:
[0106] In another aspect, the present invention provides a method for producing a composition comprising: (a) a powder X-ray diffraction (PXRD) pattern comprising peaks at 2θ values of 8.4 and 10.1 °2θ ± 0.2 °2θ, and optionally further comprising a peak at a 2θ value of 21.5 °2θ ± 0.2 °2θ; (b) 1657 cm -1 ±2cm -1 Wave number (cm -1 ) values, including 1595 and 1408 cm -1 ±2cm -1 Wave number (cm -1 ) values, or (c) Resonance (ppm) values of 25.2 and 37.5 ppm ± 0.2 ppm, and may further include a resonance (ppm) value of 159.3 ppm ± 0.2 ppm. 13 C solid-state NMR spectrum, or any combination of two or more of (a), (b) and (c). The present invention provides crystalline PF-07104091 monohydrate (Form 3) having the formula:
[0107] In another aspect, the present invention provides a method for producing a composition comprising: (1) (a) 8.4, 10.1 and 21.5°2θ±0.2°2θ; (b) 8.4, 10.1, 16.9 and 21.5°2θ±0.2°2θ; (c) 8.4, 10.1, 21.5 and 27.0°2θ±0.2°2θ, or (d) 8.4, 10.1, 16.9, 21.5 and 27.0°2θ±0.2°2θ A powder X-ray diffraction (PXRD) pattern including peaks at 2θ values of (2) (a) 1657, 1595 and 1408 cm -1 ±2cm -1 , (b) 1657, 1595, 1408 and 923 cm -1±2cm -1 , (c) 1657, 1595, 1408 and 1272 cm -1 ±2cm -1 ,or (d) 1657, 1595, 1408, 1272 and 923 cm -1 ±2cm -1 Wave number (cm -1 ) values, or (3) (a) 25.2 and 37.5 ppm ± 0.2 ppm; (b) 25.2, 37.5 and 159.3 ppm ± 0.2 ppm; (c) 25.2, 37.5, 151.9 and 159.3 ppm ± 0.2 ppm; (d) 25.2, 37.5, 152.5 and 159.3 ppm ± 0.2 ppm; or (e) 25.2, 37.5, 151.9, 152.5 and 159.3 ppm ± 0.2 ppm Includes resonance (ppm) values 13 C solid-state NMR spectrum, or any combination of two or more of (1)(a)-(d), (2)(a)-(d), and (3)(a)-(e). The present invention provides crystalline PF-07104091 monohydrate (Form 3) having the formula:
[0108] In another aspect, the present invention provides a pharmaceutical composition comprising crystalline PF-07104091 monohydrate (Form 3) according to any aspect or embodiment described herein and a pharma- ceutically acceptable carrier or excipient.
[0109] In another aspect, the invention provides a method of treating cancer in a subject in need thereof, comprising the step of administering to the subject a therapeutically effective amount of crystalline PF-07104091 monohydrate (Form 3), or a pharmaceutical composition comprising crystalline PF-07104091 monohydrate (Form 3), according to any aspect or embodiment described herein.
[0110] In another aspect, the invention provides a method of treating cancer in a subject in need thereof, comprising administering to the subject an amount of crystalline PF-07104091 monohydrate (Form 3) according to any aspect or embodiment described herein, or a pharmaceutical composition comprising crystalline PF-07104091 monohydrate (Form 3), and an amount of an additional anti-cancer agent, wherein the amounts of PF-07104091 monohydrate (Form 3) and the additional anti-cancer agent together are effective to treat cancer.
[0111] In another aspect, the present invention provides crystalline PF-07104091 monohydrate (Form 3) according to any aspect or embodiment described herein, or a pharmaceutical composition comprising crystalline PF-07104091 monohydrate (Form 3), for use in the treatment of cancer.
[0112] In another aspect, the present invention provides crystalline PF-07104091 monohydrate (Form 3), according to any aspect or embodiment described herein, for use in the manufacture of a medicament for the treatment of cancer.
[0113] In another aspect, the present invention provides a use of crystalline PF-07104091 monohydrate (Form 3), or a pharmaceutical composition comprising crystalline PF-07104091 monohydrate (Form 3), according to any aspect or embodiment described herein, for the treatment of cancer.
[0114] In yet another aspect, the present invention provides the use of crystalline PF-07104091 monohydrate (Form 3), according to any aspect or embodiment described herein, in the manufacture of a medicament for the treatment of cancer.
[0115] In each of the aspects and embodiments of crystalline PF-07104091 monohydrate (Form 3) described herein, the crystalline form may be substantially pure crystalline PF-07104091 monohydrate (Form 3).
[0116] Each of the embodiments described herein for crystalline PF-07104091 monohydrate (Form 3) may be combined with other such embodiments, provided that the embodiments are not mutually exclusive.
[0117] In another aspect, the present invention provides amorphous PF-07104091 (Form 4).
[0118] In some embodiments, the invention provides amorphous PF-07104091 (Form 4) having a powder X-ray diffraction (PXRD) pattern comprising broad peaks at diffraction angles (2θ) from about 5 to about 35° 2θ±0.2° 2θ.
[0119] In some embodiments, the present invention provides amorphous PF-07104091 (Form 4) having a powder X-ray diffraction (PXRD) pattern essentially the same as FIG.
[0120] In some embodiments, the present invention provides a method for producing a cellulose membrane having a glass transition temperature (T g ) (FIG. 14).
[0121] In another embodiment, the present invention provides (1) (a) a broad peak at diffraction angles (2θ) from about 5 to about 35° 2θ ± 0.2° 2θ, or (b) Peaks at essentially the same 2θ values as in Figure 4 or a powder X-ray diffraction (PXRD) pattern (2θ) comprising (2) (a) Glass transition temperature (T g ) (measured by DSC at a ramp rate of 10°C / min), or (b) DSC thermogram essentially the same as in Figure 14. DSC thermograms, including Or any combination of two or more of (1)(a)-(b) and (2)(a)-(b).
[0023] The present invention provides amorphous PF-07104091 (Form 4), having the formula:
[0122] In another aspect, the invention provides a pharmaceutical composition comprising amorphous PF-07104091 (Form 4) according to any aspect or embodiment described herein and a pharma- ceutically acceptable carrier or excipient.
[0123] In another aspect, the invention provides a method of treating cancer in a subject in need thereof, comprising the step of administering to the subject a therapeutically effective amount of amorphous PF-07104091 (Form 4), or a pharmaceutical composition comprising amorphous PF-07104091 (Form 4), according to any aspect or embodiment described herein.
[0124] In another aspect, the invention provides a method of treating cancer in a subject in need thereof, comprising administering to the subject an amount of amorphous PF-07104091 (Form 4), or a pharmaceutical composition comprising amorphous PF-07104091 (Form 4), according to any aspect or embodiment described herein, and an amount of an additional anti-cancer agent, wherein the amounts of amorphous PF-07104091 (Form 4) and the additional anti-cancer agent together are effective to treat cancer.
[0125] In another aspect, the present invention provides amorphous PF-07104091 (Form 4) according to any aspect or embodiment described herein, or a pharmaceutical composition comprising amorphous PF-07104091 (Form 4), for use in the treatment of cancer.
[0126] In another aspect, the invention provides amorphous PF-07104091 (Form 4), according to any aspect or embodiment described herein, for use in the manufacture of a medicament for the treatment of cancer.
[0127] In another aspect, the present invention provides a use of amorphous PF-07104091 (Form 4), or a pharmaceutical composition comprising amorphous PF-07104091 (Form 4), according to any aspect or embodiment described herein, for the treatment of cancer.
[0128] In yet another aspect, the invention provides the use of amorphous PF-07104091 (Form 4) according to any aspect or embodiment described herein in the manufacture of a medicament for the treatment of cancer.
[0129] In each of the aspects and embodiments of amorphous PF-07104091 (Form 4) described herein, the amorphous form may be substantially pure amorphous PF-07104091 (Form 4).
[0130] Each of the embodiments described herein for amorphous PF-07104091 (Form 4) may be combined with other such embodiments, provided that the embodiments are not mutually exclusive.
[0131] In a further aspect, the present invention provides anhydrous crystalline PF-07104091 (Form 5). Form 5 is prepared by dehydration of PF-07104091 monohydrate (Form 3). In some embodiments, PF-07104091 (Form 5) is characterized by its powder X-ray diffraction (PXRD) pattern. In other embodiments, PF-07104091 (Form 5) is characterized by its Raman spectrum. In other embodiments, PF-07104091 (Form 5) is characterized by its 13 Characterized by C solid-state NMR spectroscopy.
[0132] In further embodiments, PF-07104091 (Form 5) is characterized by any combination of two or more of these methods. Exemplary combinations including two or more of the following are provided herein: powder X-ray diffraction (PXRD) pattern (2θ), Raman spectrum wavenumbers (cm -1 )or 13 C solid state NMR spectrum (ppm). In some embodiments, PF-07104091 (Form 5) is characterized by PXRD and Raman. In other embodiments, PF-07104091 (Form 5) is characterized by PXRD and Raman. 13In other embodiments, PF-07104091 (Form 5) is characterized by Raman and 13 In other embodiments, crystalline PF-07104091 (Form 5) is characterized by PXRD, Raman and 13 Characterized by C solid-state NMR.
[0133] In one aspect, the present invention provides anhydrous crystalline PF-07104091 (Form 5), characterized by a powder X-ray diffraction (PXRD) pattern.
[0134] In another embodiment, the invention provides anhydrous crystalline PF-07104091 (Form 5) having a PXRD pattern comprising three or more peaks at 2θ values selected from the group consisting of 10.2, 12.4, 15.4, 17.2, 17.9, 19.8, 21.6, 22.5, 23.7 and 26.2 °2θ±0.2 °2θ.
[0135] In another embodiment, the invention provides anhydrous crystalline PF-07104091 (Form 5) having a PXRD pattern including: (a) one, two, three, four, five, or more than five peaks selected from the group consisting of peaks at °2θ±0.2 °2θ in Table 8, or (b) peaks at essentially the same 2θ values as in Figure 5.
[0136] In another aspect, the present invention provides anhydrous crystalline PF-07104091 (Form 5), as characterized by Raman spectroscopy.
[0137] In one embodiment, the present invention provides a method for the treatment of a cancer cell comprising administering to a patient a cancer cell comprising: (a) a compound having a cm -1 ±2cm -1 One, two, three, four, five or more wave numbers (cm -1 ) values, or (b) essentially the same wavenumbers (cm -1 The present invention provides anhydrous crystalline PF-07104091 (Form 5) having a Raman spectrum including .DELTA.(R) values.
[0138] In another aspect, the present invention provides a method for producing a composition comprising: 13 Provided is anhydrous crystalline PF-07104091 (Form 5) characterized by C solid-state NMR spectroscopy.
[0139] In some such embodiments, the present invention includes (a) one, two, three, four, five, or more than five resonance (ppm) values selected from the group consisting of the values in Table 10 in ppm ± 0.2 ppm; or (b) resonance (ppm) values essentially the same as in FIG. 13 Provided is anhydrous crystalline PF-07104091 (Form 5) with C solid-state NMR spectrum (ppm).
[0140] In another aspect, the present invention provides a method for producing a composition comprising: (a) Peaks at essentially the same 2θ values as in Figure 5; (b) Essentially the same wavenumber (cm) as in Figure 9 -1 ) value, or (c) Essentially the same resonance (ppm) values as in Figure 13; or any combination of two or more of (a), (b) and (c).
[0023] The present invention provides anhydrous crystalline PF-07104091 (Form 5), having the formula:
[0141] In another aspect, the present invention provides a pharmaceutical composition comprising anhydrous crystalline PF-07104091 (Form 5) according to any aspect or embodiment described herein and a pharma- ceutically acceptable carrier or excipient.
[0142] In another aspect, the invention provides a method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of anhydrous crystalline PF-07104091 (Form 5) or a pharmaceutical composition comprising anhydrous crystalline PF-07104091 (Form 5) according to any aspect or embodiment described herein.
[0143] In another aspect, the invention provides a method of treating cancer in a subject in need thereof, comprising administering to the subject an amount of anhydrous crystalline PF-07104091 (Form 5) according to any aspect or embodiment described herein, or a pharmaceutical composition comprising anhydrous crystalline PF-07104091 (Form 5), and an amount of an additional anti-cancer agent, wherein the amounts of PF-07104091 (Form 5) and the additional anti-cancer agent together are effective to treat cancer.
[0144] In another aspect, the present invention provides anhydrous crystalline PF-07104091 (Form 5) according to any aspect or embodiment described herein, or a pharmaceutical composition comprising anhydrous crystalline PF-07104091 (Form 5), for use in the treatment of cancer.
[0145] In another aspect, the invention provides anhydrous crystalline PF-07104091 (Form 5), according to any aspect or embodiment described herein, for use in the manufacture of a medicament for the treatment of cancer.
[0146] In another aspect, the present invention provides a use of anhydrous crystalline PF-07104091 (Form 5), or a pharmaceutical composition comprising anhydrous crystalline PF-07104091 (Form 5), according to any aspect or embodiment described herein, for the treatment of cancer.
[0147] In another aspect, the present invention provides the use of anhydrous crystalline PF-07104091 (Form 5), according to any aspect or embodiment described herein, in the manufacture of a medicament for the treatment of cancer.
[0148] In each of the aspects and embodiments of anhydrous crystalline PF-07104091 (Form 5) described herein, the crystalline form may be a substantially pure crystalline form of PF-07104091 (Form 5).
[0149] Each of the embodiments described herein for anhydrous crystalline PF-07104091 (Form 5) may be combined with other such embodiments, provided that the embodiments are not mutually exclusive.
[0150] In some embodiments of the methods and uses described herein, the cancer is breast cancer, prostate cancer, lung cancer (including non-small cell lung cancer, NSCLC and small cell lung cancer, SCLC), liver cancer (including hepatocellular carcinoma, HCC), kidney cancer (including renal cell carcinoma, RCC), bladder cancer (including urothelial carcinomas such as urothelial carcinoma of the upper urinary tract, UUTUC), ovarian cancer (including epithelial ovarian cancer, EOC), peritoneal cancer (including primary peritoneal carcinoma, PPC), fallopian tube cancer, uterine cancer, and the like. Selected from the group consisting of cervical cancer, uterine cancer (including endometrial cancer), pancreatic cancer, gastric cancer, colorectal cancer, esophageal cancer, head and neck cancer (including squamous cell carcinoma of the head and neck (SCCHN), thyroid cancer and salivary gland cancer), testicular cancer, adrenal gland cancer, skin cancer (including basal cell carcinoma and melanoma), brain tumors (including astrocytoma, meningioma and glioblastoma), sarcoma (including osteosarcoma and liposarcoma), and lymphoma (including mantle cell lymphoma, MCL).
[0151] In some embodiments of the methods and uses described herein, the cancer is SCLC. In some such embodiments, the SCLC is Rb negative or Rb deficient.
[0152] In some embodiments of the methods and uses described herein, cancer is NSCLC.In some such embodiments, NSCLC is characterized by the amplification or overexpression of cyclin E1 (CCNE1) and / or cyclin E2 (CCNE2).
[0153] In some embodiments of the methods and uses described herein, the cancer is ovarian cancer (including epithelial ovarian cancer, EOC), peritoneal cancer (including primary peritoneal cancer, PPC) or fallopian tube cancer. In some such embodiments, the cancer is characterized by the amplification or overexpression of CCNE1 and / or CCNE2.
[0154] In some embodiments of the methods and uses described herein, the cancer is TNBC. In some such embodiments, the TNBC is refractory to CDK4 / 6 inhibitors such as palbociclib.
[0155] In some embodiments of the methods and uses described herein, the cancer is HR positive, HER2 negative breast cancer, including advanced or metastatic breast cancer. In some such embodiments, the breast cancer is refractory to CDK4 / 6 inhibitors such as palbociclib.
[0156] In some embodiments of the methods and uses described herein, the cancer is an advanced or metastatic cancer. In some embodiments of the methods and uses described herein, the cancer is an early stage or non-metastatic cancer.
[0157] In other embodiments, the cancer is breast cancer, including, for example, ER positive / HR positive, HER2 negative breast cancer; ER positive / HR positive, HER2 positive breast cancer; triple negative breast cancer (TNBC); or inflammatory breast cancer. In some embodiments, the breast cancer demonstrates primary or acquired resistance to endocrine therapy, anti-HER2 targeted agents, CDK4 / CDK6 inhibition, or chemotherapy (e.g., taxanes or platins).
[0158] In some embodiments, the breast cancer is advanced or metastatic breast cancer. In some embodiments of each of the foregoing, the breast cancer is characterized by amplification or overexpression of CCNE1 and / or CCNE2.
[0159] In some embodiments of the methods provided herein, the abnormal cell growth is a cancer characterized by the amplification or overexpression of CCNE1 and / or CCNE2. In some embodiments of the methods provided herein, the subject is identified as having a cancer characterized by the amplification or overexpression of CCNE1 and / or CCNE2.
[0160] In some embodiments, the cancer is breast cancer or ovarian cancer. In some such embodiments, the cancer is breast cancer or ovarian cancer characterized by CCNE1 and / or CCNE2 amplification or overexpression. In some such embodiments, the cancer is (a) breast cancer or ovarian cancer, (b) characterized by CCNE1 or CCNE2 amplification or overexpression, or (c) both (a) and (b).
[0161] In some embodiments, the compounds of the invention are administered as a first line therapy. In other embodiments, the compounds of the invention are administered as a second (or back) line therapy.
[0162] In some embodiments, the compounds of the present invention are administered as second (or backward) line therapy after endocrine therapy and / or treatment with CDK4 / 6 inhibitors. In some embodiments, the compounds of the present invention are administered as second (or backward) line therapy after endocrine therapy, such as treatment with aromatase inhibitors, SERMs or SERDs. In some embodiments, the compounds of the present invention are administered as second (or backward) line therapy after treatment with CDK4 / 6 inhibitors (e.g., palbociclib, ribociclib or abemaciclib, or a pharmaceutically acceptable salt thereof). In some embodiments, the compounds of the present invention are administered as second (or backward) line therapy after treatment with one or more chemotherapy regimens (e.g., including taxanes or platinum agents). In some embodiments, the compounds of the present invention are administered as second (or backward) line therapy after treatment with anti-HER2 targeted agents (e.g., trastuzumab, pertuzumab, lapatinib or ado-trastuzumab emtansine (T-DM1)).
[0163] As used herein, an "effective dosage," "effective amount," or "therapeutically effective amount" of a compound or pharmaceutical composition is an amount that, when used as indicated (either alone when used as a single agent, or together with other agents when used in combination), is sufficient to affect one or more beneficial or desired outcomes, including preventing, improving, or treating the biochemical, histological, or behavioral symptoms of a disease, its complications, and intermediate pathological phenotypes present during the development of a disease. In protective use, beneficial or desired outcomes may include eliminating or reducing the risk, reducing the severity, or delaying the onset of a disease. In therapeutic use, beneficial or desired outcomes may include reducing the incidence of a disease or improving one or more symptoms thereof, reducing the dose of another drug used to treat the disease, enhancing the efficacy or safety of another drug used to treat the disease, or delaying the time to disease progression.
[0164] In the context of cancer treatment, a therapeutically effective amount refers to an amount that has the effect of (1) reducing tumor size, (2) inhibiting (i.e., slowing to some extent, preferably stopping) tumor metastasis, (3) inhibiting to some extent (i.e., slowing to some extent, preferably stopping) tumor growth or tumor invasiveness, (4) ameliorating to some extent (or preferably eliminating) one or more signs or symptoms associated with cancer, (5) reducing the dosage of other agents needed to treat the disease, and / or (6) enhancing the effect of another agent, and / or (7) slowing the progression of the disease in a patient.
[0165] Effective dosage can be administered in one or multiple doses.For the purpose of the present invention, effective dosage of drug, compound or pharmaceutical composition is sufficient to perform either directly or indirectly protective or therapeutic treatment.As understood in clinical context, effective dosage of drug, compound or pharmaceutical composition may or may not be achieved in conjunction with another drug, compound or pharmaceutical composition.
[0166] A "non-standard dosing regimen" refers to a regimen for administering an amount of a substance, agent, compound or pharmaceutical composition that differs from the amount, dose or schedule typically used for that substance, agent, compound or pharmaceutical composition in a clinical or therapeutic setting. A "non-standard dosing regimen" includes a "non-standard dose" or a "non-standard dosing schedule."
[0167] A "low-dose regimen" refers to a dosing regimen in which the amount of one or more of the substances, agents, compounds or pharmaceutical compositions in the regimen is administered in an amount or dose lower than would typically be used in a clinical or therapeutic setting for that agent, e.g., when the agent is administered as a monotherapy.
[0168] The retinoblastoma susceptibility gene (RB1) was the first tumor suppressor gene to be molecularly defined. The retinoblastoma gene product, RB, is mutated or deleted at high frequency in retinoblastoma and osteosarcoma, and at variable frequency in other tumor types, such as prostate cancer (including neuroendocrine prostate cancer), breast cancer (including triple-negative breast cancer, TNBC), lung cancer (including small cell lung cancer, SCLC and non-small cell lung cancer, NSCLC), liver cancer, bladder cancer, ovarian cancer, uterine cancer, cervical cancer, gastric cancer, esophageal cancer, head and neck cancer, glioblastoma and lymphoma. In human cancers, the function of RB can be disrupted through neutralization by binding proteins (e.g., human papillomavirus-E7 protein in cervical cancer; Ishiji, T, 2000
[0021] , J Dermatol., 27:73-86) or ultimately through deregulation of the pathway responsible for its phosphorylation.
[0169] By "RB pathway" is meant the entire molecular signaling pathway that includes retinoblastoma protein (RB) and other proteins / protein families in the pathway, including but not limited to CDK, E2f, atypical protein kinase C, and Skp2. Inactivation of the RB pathway often results from perturbation of p16INK4a, cyclin D1, and CDK4.
[0170] The terms "RB+", "RB plus", "RB proficient" or "RB positive" may be used to describe cells expressing detectable amounts of functional RB protein. RB positive includes wild-type and non-mutated RB proteins. Wild-type RB (RB-WT) is generally understood to mean a form of RB protein that is typically present in the corresponding population and has the function currently assigned to the protein. RB positive may be a cell that contains a functional RB gene. A cell that is RB positive may be a cell that is capable of encoding a detectable RB protein function.
[0171] The terms "RB-", "RB minus", "RB deficient" or "RB negative" describe several types of cells in which the function of RB is disrupted, including cells that produce undetectable amounts of functional RB protein. A cell that is RB negative can be a cell that does not contain a functional RB gene. A cell that is RB negative can also be a cell that can encode the RB protein but in which the protein does not function properly.
[0172] In some embodiments of each of the methods and uses described herein, the cancer is characterized as retinoblastoma wild type (RB-WT). In some embodiments of each of the methods and uses described herein, the cancer is characterized as RB positive or RB proficiency. Such RB positive or RB proficiency cancer contains at least some functional retinoblastoma gene. In some embodiments, such RB-WT, RB positive or RB proficiency cancer is characterized as RB1-WT, RB1 positive or RB1 proficiency cancer.
[0173] In some embodiments of each of the methods and uses described herein, cancer is characterized as RB negative or RB deficient. Such RB negative or RB deficient cancer can be characterized by loss-of-function mutation, and can code missense mutation (i.e., code wrong amino acid) or nonsense mutation (i.e., code stop codon). Alternatively, such RB negative cancer can be characterized by deletion of all or part of retinoblastoma gene. In some embodiments, such RB negative or RB deficient cancer is characterized as RB1 negative or RB1 deficient.
[0174] "Tumor" refers to a malignant or potentially malignant neoplasm or mass of tissue of any size, including primary and secondary neoplasms, when applied to a subject diagnosed with or suspected of having cancer. A solid tumor is an abnormal growth or mass of tissue that does not usually contain cysts or liquid areas. Examples of solid tumors are sarcomas, carcinomas, and lymphomas. Leukemias (cancers of the blood) do not generally form solid tumors (National Cancer Institute, Dictionary of Cancer Terms).
[0175] "Tumor burden" or "tumor burden" refers to the total amount of tumor material distributed throughout the body. Tumor burden refers to the total number of cancer cells or the total size of the tumor throughout the body, including lymph nodes and bone marrow. Tumor burden can be determined by various methods known in the art, such as, for example, using calipers, or while in the body, using imaging techniques, such as ultrasound, bone scanning, computed tomography (CT) or magnetic resonance imaging (MRI) scanning.
[0176] The term "tumor size" refers to the total size of a tumor, which can be measured as the length and width of the tumor.Tumor size can be determined by various methods known in the art, such as, for example, by measuring the size of tumor when removed from a subject, for example, by using a caliper, or while in the body, by using imaging techniques, for example, bone scan, ultrasound, CR or MRI scan.
[0177] The term "patient" or "subject" refers to any single subject for whom therapy is desired or who is participating in or used as a control in a clinical trial, epidemiological study, including humans and mammalian veterinary patients such as bovine, equine, canine, and feline. In some embodiments, the subject is a human.
[0178] In some embodiments of each of the methods and uses described herein, the patient or subject is an adult. In some embodiments, the subject is a woman or a man of any menopausal state. In some embodiments, the subject is a postmenopausal woman or a man. In some embodiments, the subject is a postmenopausal woman. In some embodiments, the subject is a premenopausal or perimenopausal woman. In some embodiments, the subject is a premenopausal or perimenopausal woman treated with a luteinizing hormone releasing hormone (LHRH) agonist. In some such embodiments, the subject is a man. In some embodiments, the subject is a man treated with an LHRH or gonadotropin releasing hormone (GnRH) agonist.
[0179] The term "treat" or "treating" cancer, as used herein, refers to administering a compound of the present invention to a subject having or diagnosed with cancer, to achieve at least one positive therapeutic effect, such as, for example, reducing the number of cancer cells, reducing tumor size, reducing the rate of cancer cell invasion into peripheral organs, or reducing the rate of tumor metastasis or tumor growth, ameliorating, alleviating, inhibiting the progression of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition. The term "treatment", as used herein, refers to the act of treating as "treating" is defined immediately above, unless otherwise indicated. The term "treating" also includes adjuvant and neoadjuvant treatment of a subject.
[0180] For the purposes of the present invention, beneficial or desired clinical results include, but are not limited to, one or more of the following: reducing (or destroying) the proliferation of neoplastic or cancerous cells; inhibiting metastasis or neoplastic cells; shrinking or reducing the size of a tumor; remission of cancer; reducing symptoms resulting from cancer; increasing the quality of life of people suffering from cancer; reducing the dose of other drugs required to treat cancer; slowing the progression of cancer; curing cancer; overcoming one or more resistance mechanisms of cancer; and / or extending the survival of cancer patients. Positive therapeutic effects in cancer can be measured in several ways (see, for example, WA Weber, Assessing tumor response to therapy, J.Nucl.Med.50 Supplement 1:1S-10S (2009)). For example, with regard to tumor growth inhibition (T / C), according to the National Cancer Institute (NCI) criteria, a T / C of 42% or less is the lowest level of antitumor activity. A T / C of less than 10% was considered a high level of antitumor activity, where T / C(%)=median treated tumor volume / median control tumor volume×100.
[0181] In some embodiments, the treatment achieved by the compounds of the invention is defined by reference to any of the following: partial response (PR), complete response (CR), overall response (OR), objective response rate (ORR), progression-free survival (PFS), radiological PFS, metastasis fee-free survival (MFS), disease-free survival (DFS) and overall survival (OS).
[0182] As used herein, the term "complete response" or "CR" refers to the disappearance of all signs of cancer in response to treatment (e.g., disappearance of all target lesions). This does not necessarily mean that the cancer has been cured.
[0183] As used herein, the term "disease-free survival" (DFS) means the length of time a patient survives without any signs or symptoms of cancer after primary treatment for that cancer has ended.
[0184] As used herein, the term "duration of response" (DoR) refers to the length of time that a tumor continues to respond to treatment without cancer growing or spreading. Treatments that demonstrate improved DoR can produce a sustainable and meaningful delay in disease progression.
[0185] As used herein, the terms "objective response" and "overall response" refer to a measurable response, including a complete response (CR) or a partial response (PR). The term "overall response rate" (ORR) refers to the sum of the complete response (CR) rate and the partial response (PR) rate.
[0186] As used herein, the term "overall survival" (OS) refers to the length of time that a patient diagnosed with a disease, such as cancer, is still alive, either from the date of diagnosis of the disease or from the start of treatment therefor. OS is typically measured as the extension of life expectancy in patients receiving a particular treatment compared to a control group of patients (i.e., taking either a different drug or a placebo).
[0187] As used herein, the term "partial response" or "PR" refers to a reduction in the size of one or more tumors or lesions, or in the extent of cancer in the body, in response to treatment. For example, in some embodiments, PR refers to at least a 30% reduction in the sum of the longest diameter (SLD) of target lesions, taking baseline SLD as reference.
[0188] As used herein, the term "progression-free survival" or "PFS" refers to the length of time during and after treatment that the disease being treated (e.g., cancer) does not worsen.PFS is also referred to as "time to tumor progression" and can include the amount of time that a patient experiences CR or PR and the amount of time that a patient experiences SD.
[0189] As used herein, the term "progressive disease" or "PD" refers to a cancer that is growing, spreading or getting worse. In some embodiments, PR refers to at least a 20% increase in the SLD of the target lesion recorded since treatment began or until the presence of one or more new lesions, taking the smallest SLD as reference.
[0190] As used herein, the term "stable disease" (SD) refers to cancer that is neither decreasing nor increasing in progression or severity.
[0191] As used herein, the term "sustained response" refers to the sustained effect of reducing tumor growth after the cessation of treatment.For example, tumor size can be the same size or smaller compared with the size at the beginning of the pharmaceutical administration phase.In some embodiments, sustained response has a duration at least the same as the treatment duration, at least 1.5 times, 2 times, 2.5 times or 3 times the treatment duration, or longer.
[0192] As used herein, the anti-cancer efficacy of a method for treating cancer, including "objective response," "complete response," "partial response," "progressive disease," "stable disease," "progression-free survival," and "duration of response," may be defined and evaluated by investigators using RECIST v1.1 (Eisenhauer et al., New response evaluation criteria in solid tumours: Revised RECIST guideline (Version 1.1), Eur J of Cancer, 2009;45(2):228-47).
[0193] In some embodiments of each of the methods and uses described herein, the invention relates to neoadjuvant therapy, adjuvant therapy, first line therapy, second line therapy, second line or back line therapy, or third line or back line therapy. In each case, as further described herein, the cancer may be localized, advanced or metastatic, and the intervention may occur at any point along the disease continuum (i.e., at any stage of the cancer).
[0194] Treatment regimens for the compounds of the present invention that are effective for treating cancer patients may vary according to factors such as the patient's condition, age and weight, and the ability of the therapy to induce an anti-cancer response in the subject. Any embodiment of the aspects of the present invention may not be effective in achieving a positive therapeutic effect in all subjects, but should be effective in a statistically significant number of subjects as determined by any statistical test known in the art, such as Student's t-test, chi-square test, Mann-Whitney U test, Kruskal-Wallis test (H test), Jonkheel-Tapstra test and Wilcon on test.
[0195] The terms "treatment regimen," "dosing protocol," and "dosing regimen" may be used interchangeably to refer to the dosage and timing of administration of either the crystalline or amorphous forms of PF-07104091 as described in the present invention, alone or in combination with additional anti-cancer agents.
[0196] "Ameliorating" means reducing or improving to some extent one or more symptoms upon treatment with a compound or drug, such as any of the crystalline or amorphous forms of PF-07104091 as described in this invention, as compared to when the compound is not administered. "Ameliorating" also includes shortening or reducing the duration of the symptoms, i.e., reducing to some extent, and preferably eliminating, the symptoms.
[0197] "Abnormal cell growth", as used herein, unless otherwise indicated, refers to cell growth that is independent of normal regulatory mechanisms (e.g., loss of contact inhibition). Abnormal cell growth can be benign (not cancerous) or malignant (cancerous). In some embodiments of the methods provided herein, the abnormal cell growth is cancer.
[0198] The abnormal cell growth includes the abnormal growth of (1) tumors characterized by amplification or overexpression of CDK2, (2) tumors characterized by amplification or overexpression of CCNE1 and / or CCNE2, (3) tumors characterized by loss or Rb, and (4) tumors that are resistant to endocrine therapy, anti-HER2 targeted agents, CDK4 / 6 inhibition or chemotherapy (e.g., taxanes or platins).
[0199] In some embodiments, the method and use of the present invention may further comprise one or more additional anti-cancer agents. In some embodiments, the additional anti-cancer agent is selected from the group consisting of antitumor agents, anti-angiogenic agents, signal transduction inhibitors and anti-proliferative agents. In some embodiments, the additional anti-cancer agent is selected from the group consisting of mitotic inhibitors, alkylating agents, antimetabolites, intercalating antibiotics, growth factor inhibitors, radiation, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, antibodies, cytotoxic agents, and endocrine therapeutic agents such as anti-androgens, androgen deprivation therapy (ADT) and anti-estrogens. The additional anti-cancer agent may comprise small molecule therapeutic agents and pharma- ceutical acceptable salts or solvates thereof, therapeutic antibodies, antibody drug conjugates (ADC), proteolysis-inducing chimeric molecules (PROTAC), or antisense molecules.
[0200] In some embodiments, the additional anticancer agent is an antiestrogen, wherein the antiestrogen is an aromatase inhibitor, a SERD or a SERM. In some embodiments, the antiestrogen is an aromatase inhibitor. In some such embodiments, the aromatase inhibitor is selected from the group consisting of letrozole, anastrozole and exemestane. In some such embodiments, the aromatase inhibitor is letrozole. In some embodiments, the antiestrogen is a SERD. In some such embodiments, the SERD is selected from the group consisting of fulvestrant, elacestrant (RAD-1901, Radius Health), SAR439859 (Sanofi), RG6171 (Roche), AZD9833 (AstraZeneca), AZD9496 (AstraZeneca), lintodestrant (G1 Therapeutics), ZN-c5 (Zentalis), LSZ102 (Novartis), D-0502 (Inventisbio), LY3484356 (Lilly) and SHR9549 (Jiansu Hengrui Medicine). In some such embodiments, the SERD is fulvestrant. In some embodiments, the anti-estrogen is a SERM. In some such embodiments, the SERM is selected from the group consisting of tamoxifen, raloxifene, toremifene, lasofoxifene, bazedoxifene and afimoxifene. In some such embodiments, the SERM is tamoxifen or raloxifene.
[0201] In some embodiments, the additional anticancer agent is an antiandrogen, such as abiraterone, apalutamide, bicalutamide, cyproterone, enzalutamide, flutamide, or nilutamide. In some embodiments, the method or use further comprises androgen deprivation therapy (ADT), such as a luteinizing hormone releasing hormone (LHRH) agonist, an LHRH antagonist, a gonadotropin releasing hormone (GnRH) agonist, or a GnRH antagonist.
[0202] In some embodiments, the methods and uses of the invention further comprise one or more additional anti-cancer agents selected from the following:
[0203] Anti-angiogenic agents include, for example, VEGF inhibitors, VEGFR inhibitors, TIE-2 inhibitors, PDGFR inhibitors, angiopoietin inhibitors, PKCβ inhibitors, COX-2 (cyclooxygenase II) inhibitors, integrin (alpha-v / beta-3), MMP-2 (matrix-metalloproteinase 2) inhibitors and MMP-9 (matrix-metalloproteinase 9) inhibitors.
[0204] Signal transduction inhibitors include, for example, kinase inhibitors (e.g., inhibitors of tyrosine kinases, serine / threonine kinases, or cyclin-dependent kinases), proteasome inhibitors, PI3K / AKT / mTOR pathway inhibitors, phosphoinositide 3-kinase (PI3K) inhibitors, isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) inhibitors, B-cell lymphoma 2 (BCL2) inhibitors, neurotrophin receptor kinase (NTRK) inhibitors, rearranged upon transfection (RET) inhibitors, Notch inhibitors, PARP inhibitors, Hedgehog pathway inhibitors, and selective inhibitors of nuclear export (SINE).
[0205] Examples of signal transduction inhibitors include acalabrutinib, afatinib, alectinib, alpelisib, axitinib, binimetinib, bortezomib, bosutinib, brigutinib, cabozantinib, carfilzomib, ceritinib, cobimetinib, copanlisib, crizotinib, dabrafenib, dacomitinib, dasatinib, duvelisib, enasidenib, encorafenib, entrectinib, erlotinib, gefitinib, gilteritinib, glasdegib, ibrutinib, idelalisib, imatinib, ipa including, but not limited to, tasertib, ivosidenib, ixazomib, lapatinib, larotrectinib, lenvatinib, lorlatinib, midostaurin, neratinib, nilotinib, niraparib, olaparib, osimertinib, pazopanib, ponatinib, regorafenib, rucaparib, ruxolitinib, sonidegib, sorafenib, sunitinib, talazoparib, trametinib, vandetanib, vemurafenib, venetoclax and vismodegib, or pharmaceutically acceptable salts and solvates thereof.
[0206] Anti-neoplastic agents include, for example, alkylating agents, platinum coordination complexes, cytotoxic antibiotics, antimetabolies, biological response modifiers, histone deacetylate (HDAC) inhibitors, hormonal agents, monoclonal antibodies, growth factor inhibitors, taxanes, topoisomerase inhibitors, vinca alkaloids, and miscellaneous agents.
[0207] Alkylating agents include altretamine, bendamustine, busulfan, carmustine, chlorambucil, cyclophosphamide, dacarbazine, ifosfamide, lomustine, mechlorethamine, melphalan, procarbazine, streptozocin, temozolomide, thiotepa, and trabectedin.
[0208] Platinum coordination complexes (also referred to herein as "platinum agents") include carboplatin, cisplatin, and oxaliplatin.
[0209] Cytotoxic antibiotics include bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, mitomycin, mitoxantrone, plicamycin and valrubicin.
[0210] Antimetabolites include antifolates such as methotrexate, pemetrexed, pralatrexate, and trimetrexate; purine analogs such as azathioprine, cladribine, fludarabine, mercaptopurine, and thioguanine; and pyrimidine analogs such as azacitidine, capecitabine, cytarabine, decitabine, floxiridine, fluorouracil, gemcitabine, and trifluridine / tipracil.
[0211] Biological response modifiers include aldesleukin (IL-2), denileukin diftitox and interferon gamma.
[0212] Histone deacetylase inhibitors include belinostat, panobinostat, romidepsin and vorinostat.
[0213] Hormonal agents include antiandrogens, antiestrogens, gonadotropin releasing hormone (GnRH) analogs and peptide hormones. Examples of antiestrogens include aromatase inhibitors such as letrozole, anastrozole, and exemestane; SERDs such as fulvestrant, elacestrant (RAD-1901, Radius Health), SAR439859 (Sanofi), RG6171 (Roche), AZD9833 (AstraZeneca), AZD9496 (AstraZeneca), lintodestrant (G1 Therapeutics), ZN-c5 (Zentalis), LSZ102 (Novartis), D-0502 (Inventisbio), LY3484356 (Lilly), SHR9549 (Jiansu Hengrui Medicine); and serMs such as tamoxifen, raloxifene, toremifene, lasofoxifene, bazedoxifene, afimoxifene. Examples of GnRH analogs include degarelix, goserelin, histrelin, leuprolide and triptorelin. Examples of peptide hormones include lanreotide, octreotide and pasireotide. Examples of antiandrogens include abiraterone, apalutamide, bicalutamide, cyproterone, enzalutamide, flutamide and nilutamide, and pharmaceutically acceptable salts and solvates thereof.
[0214] Monoclonal antibodies include alemtuzumab, atezolizumab, avelumab, bevacizumab, blinatumomab, brentuximab, cemiplimab, cetuximab, daratumumab, dinutuximab, durvalumab, elotuzumab, gemtuzumab, inotuzumab ozogamicin, ipilimumab, mogamulizumab, moxetumomab pasudotox, necitumumab, nivolumab, ofatumumab, olaratumumab, panitumumab, pembrolizumab, pertuzumab, ramucirumab, rituximab, tositumomab, and trastuzumab.
[0215] Taxanes include cabazitaxel, docetaxel, paclitaxel and albumin-stabilized nanoparticle paclitaxel (Nab-paclitaxel).
[0216] Topoisomerase inhibitors include etoposide, irinotecan, teniposide and topotecan.
[0217] Vinca alkaloids include vinblastine, vincristine and vinorelbine, and pharma- ceutically acceptable salts thereof.
[0218] Miscellaneous antineoplastic agents include asparaginase (pegaspargase), bexarotene, eribulin, everolimus, hydroxyurea, ixabepilone, lenalidomide, mitotane, omacetaxine, pomalidomide, tagraxofusp, telotristat, temsirolimus, thalidomide, and venetoclax.
[0219] In some embodiments, the additional anticancer agent is abiraterone acetate, acalabrutinib, adotrastuzumab emtansine, afatinib dimaleate, affimoxifen, aldesleukin, alectinib, alemtuzumab, alpelisib, amifostine, anastrozole, apalutamide, aprepitant, arsenic trioxide, asparaginase Erwinia chrysanthemis chrysanthemi), atezolizumab, avapritinib, avelumab, axicaptidine ciloreucel, axitinib, azacitidine, AZD9833 (AstraZeneca), AZD9496 (AstraZeneca), bazedoxifene, belinostat, bendamustine hydrochloride, bevacizumab, bexarotene, bicalutamide, binimetinib, bleomycin sulfate, blinatumomab, bortezomib, bosutinib, brentuximab Buvedotin, brigutinib, cabazitaxel, cabozantinib S-malate, calaspargase pegol-mknl, capecitabine, caplacizumab-yhdp, capmatinib hydrochloride, carboplatin, carfilzomib, carmustine, cemiplimab-rwlc, ceritinib, cetuximab, chlorambucil, cisplatin, cladribine, clofarabine, cobimetinib, copanlisib hydrochloride, crizotinib, cyclophosphamide, cytarabine, D -0502 (Inventisbio), Dabrafenib mesylate, Dacarbazine, Dacomitinib, Dactinomycin, Daratumumab, Daratumumab and hyaluronidase-fihj, Darbepoetin alfa, Darolutamide, Dasatinib, Daunorubicin hydrochloride, Decitabine, Defibrotide sodium, Degarelix, Denileukin diftitox, Denosumab, Dexamethasone, Dexrazoxane hydrochloride, Dinutuximab, Docetaxel , doxorubicin hydrochloride, durvalumab, duvelisib, elacestrant, elotuzumab, eltrombopag olamine, emapalumab-lzsg, enasidenib mesylate, encorafenib, enfortumab vedotin-ejfv, entrectinib, enzalutamide, epirubicin hydrochloride, epoetin alfa, erdafitinib, eribulin mesylate, erlotinib hydrochloride, etoposide, etoposide phosphate, everolimus, exemestane,fam-trastuzumab deruxtecan-nxki, fedratinib hydrochloride, filgrastim, fludarabine phosphate, fluorouracil, flutamide, fostamatinib disodium, fulvestrant, gefitinib, gemcitabine hydrochloride, gemtuzumab ozogamicin, gilteritinib fumarate, glasdegib maleate, glucarpidase, goserelin acetate, granisetron, granisetron hydrochloride, hydroxyurea, ibritumomab tiuxetan, ibrutinib, idarubicin hydrochloride, idelalisib, ifosfamide, imatinib mesylate ib, imiquimod, inotuzumab ozogamicin, interferon alpha-2b recombinant, iobenguane I-131, ipatasertib, ipilimumab, irinotecan hydrochloride, isatuximab-irfc, ivosidenib, ixabepilone, ixazomib citrate, lanreotide acetate, lapatinib tosylate, larotrectinib sulfate, lasofoxifene, lenalidomide, lenvatinib mesylate, letrozole, leucovorin calcium, leuprolide acetate, lomustine, lorlatinib, LSZ102 (Novartis), lurbinectedi LY3484356 (Lilly), megestrol acetate, melphalan, melphalan hydrochloride, mercaptopurine, methotrexate, midostaurin, mitomycin, mitoxantrone hydrochloride, mogamulizumab-kpkc, moxetumomab-tdfk, necitumumab, nelarabine, neratinib maleate, nilotinib, nilutamide, niraparib tosilate monohydrate, nivolumab, obinutuzumab, ofatumumab, olaparib, omacetaxine mepesuccinate, ondansetron hydrochloride, osimertinib mesylate, oxaliplatin Liplatin, paclitaxel, paclitaxel albumin-stabilized nanoparticle formulation, palifermin, palonosetron hydrochloride, pamidronate disodium, panitumumab, panobinostat, pazopanib hydrochloride, pegaspargase, pegfilgrastim, peginterferon alfa-2b, pembrolizumab, pemetrexed disodium, pemigatinib, pertuzumab, pexidartinib hydrochloride, plerixafor, polatuzumab vedotin-piiq, pomalidomide, ponatinib hydrochloride, pralatrexate, prednisone, procarbazine hydrochloride,Propranolol hydrochloride, radium-223 dichloride, raloxifene hydrochloride, ramucirumab, rasburicase, ravulizumab-cwvz, recombinant interferon alfa-2b, regorafenib, RG6171 (Roche), linddestran, ripretinib, rituximab, rolapitant hydrochloride, romidepsin, romiplostim, rucaparib camsilate, ruxolitinib phosphate, sacituzumab govitecan-hziy, SAR439859 (Sanofi), selinexor, selpercatinib, selumetinib sulfate, SHR9549 (Jiansu Hengrui Medicine), siltuximab, sipuleucel-t, sonidegib, sorafenib tosilate, tagraxofusp-erzs, talazoparib tosilate, talimogene laherparepvec, tamoxifen citrate, tazemetostat hydrobromide, temozolomide, temsirolimus, thalidomide, thioguanine, thiotepa, tisagenlecleucel, tocilizumab, topotecan hydrochloride, toremifene, trabectedin, trametinib, trastuzumab, trastuzumab and hyaluronidase-oysk, Trifluridine and tipiracil hydrochloride, tucatinib, uridine triacetate, valrubicin, vandetanib, vemurafenib, venetoclax, vinblastine sulfate, vincristine sulfate, vinorelbine tartrate, vismodegib, vorinostat, zanubrutinib, ziv-aflibercept, ZN-c5 (Zentalis), and zoledronic acid; or a free base, pharma- ceutically acceptable salt (including alternate salt forms of the above-named salts), or solvated form of the foregoing; or a combination thereof.
[0220] The term "cancer" or "cancerous" refers to or describes a tumor caused by malignant and / or invasive growth, or abnormal cell growth. As used herein, "cancer" refers to solid tumors, named for the type of cells that form them, and cancers of the blood, bone marrow, or lymphatic system. Examples of solid tumors include, but are not limited to, sarcomas and carcinomas. Examples of blood cancers include, but are not limited to, leukemia, lymphoma, and myeloma. The term "cancer" includes, but is not limited to, primary cancers that originate at a specific site in the body, metastatic cancers that have spread from where it began to other parts of the body, recurrences from a first primary cancer after remission, and second primary cancers, which are new primary cancers in people with a history of previous cancers that are different in type from the later one.
[0221] The efficacy of the methods and uses described herein in certain tumors may be enhanced by combination with other approved or experimental cancer therapies, such as radiation, surgery, chemotherapeutic agents, targeted therapies, agents that inhibit other signaling pathways that are dysregulated in tumors, and other immune enhancing agents such as PD-1 or PD-L1 antagonists, etc. The methods and uses of the present invention may further include one or more additional anti-cancer agents.
[0222] Administration of the crystalline or amorphous forms of the invention may be effected by any method that allows delivery of the compound to the site of action, including oral routes, intraduodenal routes, parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion), topical and rectal administration.
[0223] Dosage regimen can be adjusted to provide the optimum desired response. For example, the crystalline or amorphous form of the present invention can be administered as a single bolus, as several divided doses administered over time, or the dose can be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It can be particularly advantageous to formulate therapeutic agents in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form, as used herein, refers to physically discrete units suitable as unit dosages for treating mammalian subjects, each unit containing a predetermined amount of active compound calculated to produce a desired therapeutic effect together with the required pharmaceutical carrier. The specifications for the dosage unit form of the present invention can be dictated by and directly depend on (a) the unique characteristics of the solid form and the specific therapeutic or protective effect to be achieved, and (b) the limitations inherent in the technical field of compounding such as active compounds for treating sensitivities in individuals.
[0224] Therefore, based on the disclosure provided herein, those skilled in the art will understand that dosage and administration regimen can be adjusted according to the method well known in the art of treatment.That is, the maximum tolerated dose can be easily established, as can the temporal requirement for administering each agent to provide detectable therapeutic benefit to the subject, and the effective amount that provides detectable therapeutic benefit to the subject can also be determined.Therefore, although certain dosage and administration regimen are exemplified herein, these examples do not limit the dosage and administration regimen that can be provided to the subject when implementing the present invention.
[0225] It should be noted that dosage values may vary with the type and severity of the condition to be alleviated, and may include single or multiple doses. It should further be understood that for any particular subject, the specific dosage regimen should be adjusted over time, taking into account factors such as the severity of the disorder or condition, the rate of administration, the pharmacokinetics of the compound, and the discretion of the prescribing physician, according to the individual need and the professional judgment of the person administering or supervising the administration of the compound or pharmaceutical composition. The dosage ranges specified herein are exemplary only, and are not intended to limit the scope or practice of the claimed solid forms or pharmaceutical compositions. For example, the dose may be adjusted based on pharmacokinetic or pharmacodynamic parameters, which may include toxic effects and / or clinical effects such as laboratory values. Thus, the present invention encompasses intra-patient dose escalation as determined by those skilled in the art. It will be understood that determining the appropriate dosage and regimen for administration of chemotherapeutic agents is well known in the relevant art, and would be encompassed by those skilled in the art once provided with the teachings disclosed herein.
[0226] The dosage of the crystalline or amorphous forms of the present invention is typically within the range of about 0.001 to about 100 mg per kg of body weight per day, preferably about 1 to about 35 mg / kg / day, in single or divided doses. For a 70 kg human, this would amount to about 0.01 to about 7 g / day, preferably about 0.02 to about 2.5 g / day. In some cases, dosage levels below the lower limit of the range may be more than sufficient, while in other cases, larger doses may be used without causing any adverse side effects, provided that such larger doses are first divided into several smaller doses for administration throughout the day. The dosage may be administered as a single dose (QD) or may be optionally subdivided into smaller doses suitable for BID (twice a day), TID (three times a day) or QID (four times a day) administration. The dosage regimen may be adjusted to provide the optimal therapeutic response. For example, doses may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation, including temporary or permanent dose reduction as needed to ameliorate or prevent side effects.
[0227] Repeated administration or dosing regimen or adjustment of administration or dosing regimen can be carried out as necessary to achieve desired treatment. "Continuous dosing schedule" as used herein is an administration or dosing regimen that does not have dosing interruption, for example, no treatment holiday.Repeated 21 or 28 day treatment cycles without dosing interruption between treatment cycles is an example of a continuous dosing schedule.
[0228] In some embodiments, the crystalline or amorphous form of PF-07104091 is administered at a daily dosage of about 1 mg to about 1000 mg per day. In some embodiments, the crystalline or amorphous form of the present invention is administered at a daily dosage of about 10 mg to about 500 mg per day, and in some embodiments, at a dosage of about 25 mg to about 300 mg per day. In some embodiments, this is about 1, 2, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, Dosages of 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 260, 270, 275, 280, 290, 300, 325, 350, 375, 400, 425, 450, 475 or 500 mg administered on a QD, BID, TID or QID schedule.
[0229] Repeated administration or dosing regimen or adjustment of administration or dosing regimen can be performed as necessary to achieve desired treatment. "Intermittent dosing schedule" refers to a dosing or dosing regimen that includes a period of dosing interruption, such as a treatment holiday. Repeated 14 or 21 day treatment cycles with 7 days of treatment interruption between treatment cycles is an example of an intermittent dosing schedule. Such a schedule of 2 or 3 weeks on treatment and 1 week off treatment is sometimes referred to as 2 / 1 week or 3 / 1 week treatment cycle, respectively. Alternatively, intermittent dosing can include a 7 day treatment cycle with 5 days on treatment and 2 days off treatment.
[0230] A "continuous dosing schedule," as used herein, is an administration or dosing regimen that does not include a dosing break, e.g., no treatment holidays. Repeated 21- or 28-day treatment cycles with no dosing break between treatment cycles is an example of a continuous dosing schedule.
[0231] In some embodiments, any of the crystalline or amorphous forms of PF-07104091 described herein are administered on an intermittent dosing schedule. In other embodiments, any of the crystalline or amorphous forms of PF-07104091 described herein are administered on a continuous dosing schedule.
[0232] A "pharmaceutical composition" refers to a mixture of one or more of the therapeutic agents described herein as an active ingredient, or a pharma- ceutically acceptable salt, solvate, hydrate, or prodrug thereof, and at least one pharma- ceutically acceptable carrier or excipient. In some embodiments, a pharmaceutical composition comprises two or more pharma- ceutically acceptable carriers and / or excipients.
[0233] As used herein, a "pharmaceutically acceptable carrier" refers to a carrier or excipient that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of an active compound or therapeutic agent.
[0234] Pharmaceutically acceptable carriers can include any conventional pharmaceutical carrier or excipient. The choice of carrier and / or excipient will depend to a large extent on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form.
[0235] In one embodiment, the present invention relates to a pharmaceutical composition comprising anhydrous crystalline PF-07104091 (Form 2) and a pharma- ceutically acceptable carrier or excipient.
[0236] In one embodiment, the present invention relates to a pharmaceutical composition comprising crystalline PF-07104091 monohydrate (Form 3) and a pharma- ceutically acceptable carrier or excipient.
[0237] In one embodiment, the present invention relates to a pharmaceutical composition comprising amorphous PF-07104091 (Form 4) and a pharma- ceutically acceptable carrier or excipient.
[0238] In one embodiment, the present invention relates to a pharmaceutical composition comprising anhydrous crystalline PF-07104091 (Form 5) and a pharma- ceutically acceptable carrier or excipient.
[0239] Suitable pharmaceutical carriers include inert diluents or fillers, water and various organic solvents (such as hydrates and solvates). Pharmaceutical compositions may contain additional ingredients such as flavorings, binders, additives, etc., if desired. Thus, for oral administration, tablets containing various additives such as citric acid may be used with various disintegrants such as starch, alginic acid and certain complex silicates, and binders such as sucrose, gelatin and acacia. Examples of additives include, but are not limited to, calcium carbonate, calcium phosphate, various sugars and various starches, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols. In addition, lubricants such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tableting purposes. Similar types of solid pharmaceutical compositions may also be used in soft and hard filled gelatin capsules. Thus, non-limiting examples of materials include lactose or milk sugar and high molecular weight polyethylene glycols. When aqueous suspensions or elixirs are desired for oral administration, the active compound therein may be combined with various sweetening or flavoring agents, coloring substances or dyes, and, if desired, emulsifying or suspending agents, together with excipients such as water, ethanol, propylene glycol, glycerin, or combinations thereof.
[0240] The pharmaceutical composition of the present invention may be in a form suitable for oral administration, for example, as a tablet, capsule, pill, powder, sustained release formulation, liquid, or suspension, for parenteral injection as a sterile solution, suspension, or emulsion, for topical administration as an ointment or cream, or for rectal administration as a suppository.The pharmaceutical composition may be in a unit dosage form suitable for single administration of an accurate dosage.The pharmaceutical composition will include a conventional pharmaceutical carrier or additive and a compound according to the present invention as an active ingredient.In addition, the composition may include other medicinal or pharmaceutical agents, carriers, adjuvants, etc.
[0241] Exemplary parenteral administration forms include solutions or suspensions of active compounds in sterile aqueous solutions, for example aqueous propylene glycol or dextrose solutions. Such dosage forms may be suitably buffered, if desired.
[0242] Methods for preparing various pharmaceutical compositions containing specific amounts of active compounds are known or will be apparent to those skilled in the art, see, for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easter, Pa., 19th Edition (1995).
[0243] Either the crystalline or amorphous forms of the invention described herein may be administered orally, which may involve swallowing so that the therapeutic agent enters the digestive tract, or buccal or sublingual administration may be used where the therapeutic agent enters the bloodstream directly from the mouth.
[0244] Formulations suitable for oral administration include solid formulations such as capsules containing tablets, particles, liquids or powders, lozenges (containing liquid fills), chewable tablets, multi- and nanoparticles, gels, solid liquids, liposomes, films (including mucoadhesives), ovules, sprays and liquid formulations.
[0245] Liquid formulations include suspensions, solutions, syrups and elixirs.Such formulations can be used as fillers in soft or hard capsules, and typically can include carriers such as water, ethanol, polyethylene glycol, propylene glycol, methylcellulose or suitable oils, and one or more emulsifiers and / or suspending agents.Liquid formulations can also be prepared by the reconstitution of solids, for example from sachets.
[0246] Either the crystalline or amorphous forms of the invention described herein may be used in fast-dissolving, fast-disintegrating dosage forms such as those described in Expert Opinion in Therapeutic Patents, 11(6), 981-986, by Liang and Chen (2001), the disclosure of which is incorporated herein by reference in its entirety.
[0247] In tablet dosage forms, the crystalline or amorphous form of PF-07104091 may comprise 1 weight percent (wt%) to 80 wt% of the dosage form, more typically 5 wt% to 60 wt% of the dosage form. In addition to the active agent, tablets generally contain a disintegrant. Examples of disintegrants include sodium starch glycolate, sodium carboxymethylcellulose, calcium carboxymethylcellulose, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methylcellulose, microcrystalline cellulose, lower alkyl-substituted hydroxypropylcellulose, starch, pregelatinized starch, and sodium alginate. Generally, the disintegrant may comprise 1 wt% to 25 wt%, preferably 5 wt% to 20 wt% of the dosage form.
[0248] Binders are generally used to impart adhesive qualities to tablet formulations.Suitable binders include microcrystalline cellulose, gelatin, sugar, polyethylene glycol, natural and synthetic gums, polyvinylpyrrolidone, pregelatinized starch, hydroxypropyl cellulose and hydroxypropyl methylcellulose.Tablets may also contain excipients such as lactose (monohydrate, spray-dried monohydrate, anhydrous, etc.), mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starch and calcium hydrogen phosphate dihydrate.
[0249] Tablets may optionally contain surface active agents such as sodium lauryl sulfate and polysorbate 80, and glidants such as silicon dioxide and talc. If present, surface active agents typically amount to from 0.2 wt% to 5 wt% of the tablet, and glidants typically amount to from 0.2 wt% to 1 wt% of the tablet.
[0250] Tablets generally also contain a lubricant such as magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, and mixtures of magnesium stearate with sodium lauryl sulfate. Lubricants are generally present in an amount from 0.25 wt% to 10 wt%, preferably from 0.5 wt% to 3 wt% of the tablet.
[0251] Other conventional ingredients include antioxidants, colorants, flavorants, preservatives and taste-masking agents.
[0252] An exemplary tablet may contain from about 1 wt% to about 80 wt% active agent, from about 10 wt% to about 90 wt% binder, from about 0 wt% to about 85 wt% excipient, from about 2 wt% to about 10 wt% disintegrant, and from about 0.25 wt% to about 10 wt% lubricant.
[0253] Tablet blends can be directly or by roller compression to form tablets. Tablet blends or portions of blends can alternatively be wet-, dry- or melt-granulated, melt congealed or extruded before tableting. The final formulation can include one or more layers, can be coated or uncoated, or can be encapsulated.
[0254] Tablet formulation is discussed in detail in "Pharmaceutical Dosage Forms: Tablets, Vol. 1," by H. Lieberman and L. Lachman, Marcel Dekker, NY, NY, 1980 (ISBN 0-8247-6918-X), the disclosure of which is incorporated herein by reference in its entirety.
[0255] Capsules (e.g., made from gelatin or HPMC), blisters and cartridges for use in an inhaler or insufflator may be formulated to contain a powder mix of a therapeutic agent, a suitable powder base, such as lactose or starch, and a performance modifier, such as l-leucine, mannitol or magnesium stearate. The lactose may be anhydrous or in the form of the monohydrate, preferably the latter. Other suitable excipients include dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose and trehalose.
[0256] Solid formulations for oral administration may be formulated to be immediate and / or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
[0257] Suitable modified release formulations are described in U.S. Patent No. 6,106,864. Details of other suitable release technologies, such as high energy dispersions and osmotic and coated particles, can be found in Verma et al., Current Status of Drug Delivery Technologies and Future Directions, Pharmaceutical Technology On-line, (2001) 25:1-14. The use of chewing gum to achieve controlled release is described in WO00 / 35298. The disclosures of these references are incorporated herein in their entirety by reference.
[0258] Any of the crystalline or amorphous forms of PF-07104091 described herein may be administered directly into the bloodstream, into muscle or into internal organs. Suitable means for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular and subcutaneous. Suitable devices for parenteral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.
[0259] Parenteral formulations are typically aqueous solutions which may contain additives such as salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), although for some applications they may be more suitably formulated as sterile non-aqueous solutions or as a dry form for use in conjunction with a suitable vehicle such as sterile pyrogen-free water.
[0260] The preparation of parenteral formulations under sterile conditions, for example, by lyophilization, may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art.
[0261] The solubility of therapeutic agents used in the preparation of parenteral solutions may potentially be increased by the use of appropriate formulation techniques, such as the incorporation of solubility-enhancing agents.
[0262] The crystalline and amorphous forms of PF-07104091 described herein may be in the form of a kit suitable for administering the pharmaceutical composition. Such a kit may include the active agent in the form of a pharmaceutical composition, which includes the active agent, or a pharma- ceutically acceptable salt or solvate thereof, and a pharma- ceutically acceptable carrier. The kit may contain a means for separately holding the pharmaceutical composition, such as a container, a divided bottle, or a divided foil packet. An example of such a kit is a home blister pack used for packaging tablets, capsules, and the like. To aid in compliance, the kit typically includes administration instructions and may be equipped with a memory aid. The kit may further include other materials that may be useful in administering the medicament, such as excipients, filters, IV bags and lines, needles and syringes.
[0263] In some preferred embodiments, the invention provides one or more of embodiments E1 to E41.
[0264] E1. A crystalline form of (1R,3S)-3-[3-({[3-(methoxymethyl)-1-methyl-1H-pyrazol-5-yl]carbonyl}amino)-1H-pyrazol-5-yl]cyclopentylpropan-2-ylcarbamate (PF-07104091) monohydrate (Form 3) having a powder X-ray diffraction (PXRD) pattern including peaks at 2θ values measured using CuKα radiation of 8.4, 10.1, and 21.5 °2θ ± 0.2 °2θ.
[0265] E2. The crystalline form of embodiment E1 having a PXRD pattern further including a peak at a 2θ value measured using CuKα radiation of 16.9°2θ±0.2°2θ.
[0266] E3. The crystalline form of embodiment E1 or E2 having a PXRD pattern further comprising a peak at a 2θ value measured using CuKα radiation of 27.0°2θ±0.2°2θ.
[0267] E4. 1657cm -1 ±2cm -1 Wave number (cm -1 The crystalline form of any one of embodiments E1 to E3 having a Raman spectrum comprising:
[0268] E5. 1595cm -1 ±2cm -1 Wave number (cm -1 The crystalline form of embodiment E4 having a Raman spectrum further comprising:
[0269] E6. 1408cm -1 ±2cm -1 Wave number (cm -1 The crystalline form of embodiment E4 or E5 having a Raman spectrum further comprising a ) value.
[0270] E7. Contains one, two or three resonance (ppm) values selected from the group consisting of 25.2, 37.5 and 159.3 ppm ± 0.2 ppm. 13The crystalline form of any one of embodiments E1 to E6 having a C solid state NMR spectrum.
[0271] E8. Further including resonance (ppm) values of 151.9 and 152.5 ppm ± 0.2 ppm 13 The crystalline form of embodiment E7 having a C solid state NMR spectrum.
[0272] E9. 1657, 1595 and 1408 cm -1 ±2cm -1 Wave number (cm -1 ) values.
[0273] E10. Resonance (ppm) values of 25.2 and 37.5 ppm ± 0.2 ppm, and may further include a resonance (ppm) value of 159.3 ppm ± 0.2 ppm. 13 A crystalline form of PF-07104091 monohydrate (Form 3) with a C solid-state NMR spectrum.
[0274] E11. The crystalline form of embodiment E10 having a PXRD pattern including peaks at 2θ values measured using CuKα radiation of 8.4 and 10.1 degrees 2θ±0.2 degrees 2θ.
[0275] E12. 1657cm -1 ±2cm -1 Wave number (cm -1 The crystalline form of embodiment E10 or E11 having a Raman spectrum comprising:
[0276] E13. (a) a PXRD pattern including peaks at 2θ values measured using CuKα radiation of 8.4, 10.1 and 21.5°2θ±0.2°2θ; (b) 1657, 1595 and 1408 cm -1 ±2cm -1 Wave number (cm -1 ) values, or (c) Includes resonance (ppm) values of 25.2, 37.5 and 159.3 ppm ± 0.2 ppm 13 C solid-state NMR spectrum, or any combination of two or more of (a), (b) and (c). A crystalline form of PF-07104091 monohydrate (Form 3), having the formula:
[0277] E14. (a) a PXRD pattern including peaks at 2θ values measured using CuKα radiation of 8.4 and 10.1 °2θ ± 0.2 °2θ, and optionally further including a peak at a 2θ value measured using CuKα radiation of 21.5 °2θ ± 0.2 °2θ; (b) 1657 cm -1 ±2cm -1 Wave number (cm -1 ) values, including 1595 and 1408 cm -1 ±2cm -1 Wave number (cm -1 ) values, or (c) Resonance (ppm) values of 25.2 and 37.5 ppm ± 0.2 ppm, and may further include a resonance (ppm) value of 159.3 ppm ± 0.2 ppm. 13 C solid-state NMR spectrum, or any combination of two or more of (a), (b) and (c). A crystalline form of PF-07104091 monohydrate (Form 3), having the formula:
[0278] E15. The crystalline form of any one of embodiments E1 to E14, which is substantially pure PF-07104091 monohydrate (Form 3).
[0279] E16. An anhydrous crystalline form of PF-07104091 (Form 2) having a PXRD pattern including peaks at 2θ values measured using CuKα radiation: 9.8, 13.3, and 17.4 °2θ±0.2 °2θ.
[0280] E17. The crystalline form of embodiment E16 having a PXRD pattern further comprising a peak at a 2θ value measured using CuKα radiation of 4.2°2θ±0.2°2θ.
[0281] E18. The crystalline form of embodiment E16 or E17 having a PXRD pattern further comprising a peak at a 2θ value measured using CuKα radiation of 7.5°2θ±0.2°2θ.
[0282] E19. 1691cm -1 ±2cm -1 Wave number (cm -1 The crystalline form of any one of embodiments E16 to E18 having a Raman spectrum comprising:
[0283] E20. 1582cm -1 ±2cm -1 Wave number (cm -1 The crystalline form of embodiment E19 having a Raman spectrum further comprising a ) value.
[0284] E21. 996cm -1 ±2cm -1 Wave number (cm -1 The crystalline form of embodiment E19 or E20 having a Raman spectrum further comprising a ) value.
[0285] E22. Contains one, two or three resonance (ppm) values selected from the group consisting of 24.1, 39.8 and 41.6 ppm ± 0.2 ppm. 13 The crystalline form of any one of embodiments E16 to E21 having a C solid state NMR spectrum.
[0286] E23. Further includes resonance (ppm) values of 21.8 and 138.2 ppm ± 0.2 ppm. 13 The crystalline form of embodiment E22 having a C solid state NMR spectrum.
[0287] E24. 1691, 1582 and 996cm -1 ±2cm -1Wave number (cm -1 ) values.
[0288] E25. Includes resonance (ppm) values of 24.1, 39.8 and 41.6 ppm ± 0.2 ppm 13 Anhydrous crystalline form of PF-07104091 (Form 2) with C solid-state NMR spectrum.
[0289] E26. The crystalline form of embodiment E25 having a PXRD pattern including peaks at 2θ values measured using CuKα radiation of 9.8 and 13.3 °2θ±0.2 °2θ.
[0290] E27. 1691cm -1 ±2cm -1 Wave number (cm -1 The crystalline form of embodiment E25 or E26 having a Raman spectrum comprising:
[0291] E28. (a) a PXRD pattern including peaks at 2θ values measured using CuKα radiation of 9.8, 13.3 and 17.4°2θ±0.2°2θ; (b) 1691, 1582 and 996 cm -1 ±2cm -1 Wave number (cm -1 ) values, or (c) Includes resonance (ppm) values of 24.1, 39.8 and 41.6 ppm ± 0.2 ppm 13 C solid-state NMR spectrum, or any combination of two or more of (a), (b) and (c). The anhydrous crystalline form of PF-07104091 (Form 2),
[0292] E29. (a) a PXRD pattern including peaks at 2θ values measured using CuKα radiation of 9.8 and 13.3°2θ±0.2°2θ, and optionally further including a peak at a 2θ value measured using CuKα radiation of 17.4°2θ±0.2°2θ; (b) 1691 cm -1 ±2cm -1 Wave number (cm -1 ) values, including 1582 and 996 cm -1 ±2cm -1 Wave number (cm -1 ) values, or (c) Includes resonance (ppm) values of 24.1, 39.8 and 41.6 ppm ± 0.2 ppm 13 C solid-state NMR spectrum, or any combination of two or more of (a), (b) and (c). The anhydrous crystalline form of PF-07104091 (Form 2),
[0293] E30. The crystalline form of any one of embodiments E16 to E29, which is substantially pure PF-07104091 (Form 2).
[0294] E31. An anhydrous crystalline form of PF-07104091 (Form 5) having a PXRD pattern containing three or more peaks at 2θ values measured using CuKα radiation selected from the group consisting of 10.2, 12.4, 15.4, 17.2, 17.9, 19.8, 21.6, 22.5, 23.7 and 26.2 °2θ±0.2 °2θ.
[0295] E32. A pharmaceutical composition comprising the crystalline form of any one of embodiments E1 to E31 and a pharma- ceutically acceptable carrier or excipient.
[0296] E33. A method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the crystalline form of any one of embodiments E1 to E31.
[0297] E34. The method of embodiment E33, wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, lung cancer, liver cancer, kidney cancer, bladder cancer, ovarian cancer, peritoneal cancer, fallopian tube cancer, cervical cancer, uterine cancer, pancreatic cancer, gastric cancer, colorectal cancer, esophageal cancer, head and neck cancer, testicular cancer, adrenal cancer, skin cancer, brain tumor, sarcoma and lymphoma.
[0298] E35. Amorphous form of PF-07104091 (Form 4).
[0299] E36. The amorphous form of embodiment E35 having a PXRD pattern including a broad peak at diffraction angles (2θ) measured using CuKα radiation from about 5 to about 35°2θ±0.2°2θ.
[0300] E37. An amorphous form of embodiment E35 or E36 having a PXRD pattern essentially the same as FIG.
[0301] E38. Glass transition temperature (T g The amorphous form of any one of embodiments E35 to E37, having the formula:
[0302] E39. A pharmaceutical composition comprising the amorphous form of any one of embodiments E35 to E38 and a pharma- ceutically acceptable carrier or excipient.
[0303] E40. A method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the amorphous form of any one of embodiments E35 to E38.
[0304] E41. The method of embodiment E40, wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, lung cancer, liver cancer, kidney cancer, bladder cancer, ovarian cancer, peritoneal cancer, fallopian tube cancer, cervical cancer, uterine cancer, pancreatic cancer, gastric cancer, colorectal cancer, esophageal cancer, head and neck cancer, testicular cancer, adrenal cancer, skin cancer, brain tumor, sarcoma and lymphoma. EXAMPLES
[0305] The examples and preparations provided below further illustrate and exemplify aspects and embodiments of the present invention. It is understood that the scope of the present invention is not limited by the scope of the following examples.
[0306] Example 1 Instrumental Methods General Method A. Powder X-ray Diffraction (PXRD) Instrument Law: Powder X-ray diffraction analysis was performed using a Bruker AXS D8 Endeavor diffractometer equipped with a Cu radiation source. Diffracted radiation was detected by a LynxEye XE T detector with motorized slits. X-ray tube voltage and amperage were set at 40 kV and 40 mA, respectively. Data were collected in a locked-coupled scanning theta-theta goniometer at Cu K-alpha wavelengths (CuKαλ=1.5418 Å) from 3.0 to 40.0 degrees 2-theta in 0.01 degree increments, using a scan speed of 1.0 seconds per step. The anti-scatter screen was set at a fixed distance of 1.5 mm. Samples were prepared by placing them in a silicon low background sample holder. Samples were rotated at 15 revolutions per minute during collection. Data were collected using Bruker DIFFRAC plus software.
[0307] Peak Picking Method: Data analysis was performed using Bruker DIFFRAC Plus software (version 5.0.0). No processing of the PXRD data files was performed prior to peak searching. A peak search algorithm in EVA software was applied to perform preliminary peak assignments using a threshold of 1. Adjustments were made manually, the output of the automatic assignment was visually checked, and peak positions were adjusted to the peak maximum to ensure validity. Peaks with a relative intensity of 3% or greater were generally selected. Peaks that were not resolved or matched to noise were not selected. Typical errors associated with peak positions from the PXRD as described in the USP are up to + / - 0.2° 2-theta (USP-941).
[0308] General Method B. Raman Spectroscopy Instrument Law: Raman spectra were collected using a Thermo Scientific iS50 FT-Raman accessory mounted on an FT-IR bench. A CaF2 beam splitter is utilized in the FT-Raman configuration. The spectrometer is equipped with a 1064 nm diode laser and a room temperature InGaAs detector. Prior to data acquisition, instrument performance and calibration verification was performed using polystyrene. Samples were analyzed in glass NMR tubes as tablets or in a suitable sample holder that was held statically during data collection. Spectra were collected using laser powers between 0.1 and 0.5 W and 512 co-added scans. The collection range was 3700–100 cm. -1 The API spectrum was 2cm -1 Resolution was used and Happ-Genzel apodization was utilized for all of the spectra. Multiple spectra were recorded and the spectra reported are representative of two spots.
[0309] Peak Picking Method: The intensity scale was normalized to 1 before peak picking. Peaks were manually identified using Thermo Nicolet Omnic 9.7.46 software. Peak locations were picked at the peak maximum, peaks were identified as is only if there were slopes on either side, and peak shoulders were not included. For undiluted form 3 API, an absolute threshold of 0.012 with a sensitivity of 75 was utilized during peak picking. For undiluted form 2 API, an absolute threshold of 0.04 with a sensitivity of 75 was utilized during peak picking. Peaks with normalized peak intensities between (1–0.75), (0.74–0.30), and (0.29–0) were labeled as strong, medium, and weak, respectively. Relative peak intensity values are also illustrated in this report.
[0310] General method C. 13 C solid-state NMR (ssNMR) spectroscopy: Instrument Law: Solid-state NMR (ssNMR) analysis was performed using a Bruker Biospin Avance III 500 MHz ( 1 H frequency) was performed with a CPMAS probe located within a NMR spectrometer. The material was packed into a 4 mm rotor. A magic angle spinning speed of 15.0 kHz was used.
[0311] 13 C ssNMR spectra were collected using a proton decoupled cross-polarization magic angle spinning (CPMAS) experiment. A phase-modulated proton decoupling field of 80-90 kHz was applied during the spectrum acquisition. The cross-polarization contact time was set to 2 ms. Recycle delays of 4.5 s, 3.9 s, 4.5 s and 2.4 s were used in the experiments for Form 1, Form 2, Form 3 and Form 5, respectively. The number of scans was adjusted to obtain a reasonable signal-to-noise ratio, and 768 or 1024 scans were collected for each API. 13 The C chemical shift scale is based on the external standard of crystalline adamantane. 13 A C CPMAS experiment was used, with its upfield resonance set to 29.5 ppm (determined from neat TMS) and referenced.
[0312] Peak Picking Method: Automated peak picking was performed using Bruker-Biospin Topspin version 3.6 software. A threshold of 5% relative intensity was generally used for preliminary peak selection. The output of the automated peak picking was visually checked to ensure validity, and adjustments were made manually if necessary. Although specific solid-state NMR peak values are reported herein, there is a range for these peak values due to differences in instruments, samples, and sample preparation. This is a common practice in the art of solid-state NMR due to the inherent variability in peak positions. 13 Typical variability in C chemical shift x-axis values is approximately plus or minus 0.2 ppm for crystalline solids. The solid-state NMR peak heights reported herein are relative intensities. Solid-state NMR intensities may vary depending on the actual settings of CPMAS experimental parameters and the thermal history of the sample.
[0313] Example 2 Preparation of anhydrous crystalline PF-07104091 (Form 2)
[0314] [ka] Anhydrous crystalline PF-07104091 (Form 2) was prepared by dissolving PF-07104091 monohydrate (Form 1) (prepared as described in U.S. Pat. No. 11,014,911) in 50:50% v / v methyl isobutyl ketone:heptane at approximately 80° C. The solution was then removed from the heat and allowed to cool to room temperature. The resulting solid was collected by filtration, rinsed with heptane, and dried under vacuum to provide crystalline PF-07104091 (Form 2), which was confirmed to be the anhydrous free form by elemental analysis.
[0315] PF-07104091 (Form 2) was also obtained by crystallization from other solvents (e.g., ethyl acetate, cyclohexane or mixtures thereof) as shown by PXRD analysis. In some cases, small amounts of residual solvent were detectable by ssNMR, likely due to solvent trapped within crystal lattice defects during crystallization of the anhydrous form.
[0316] Differential scanning calorimetry (DSC) showed a melting endotherm with an onset temperature of about 113° C. (confirmed by melting point apparatus).
[0317] PF-07104091 (Form 2) was found to be slightly hygroscopic by moisture sorption (DVS) studies: approximately 0.7% mass gain at 60% RH; approximately 1% mass gain at 75% RH; and approximately 1.6% mass gain at 90% RH. PXRD of the material after moisture sorption showed no change in the solid form.
[0318] Thermogravimetric analysis (TGA) on an authentic sample of Form 2 crystallized from acetone:cyclohexane (1:2.1) showed a total weight loss of approximately 1%, which was confirmed to be residual solvent (cyclohexane) by solution NMR.
[0319] [Table 1]
[0320] [Table 2-1]
[0321] [Table 2-2]
[0322] [Table 3] † indicates peaks due to trapped solvent molecules
[0323] Example 3 Preparation of crystalline PF-07104091 monohydrate (form 3)
[0324] [ka] N-(5-((1S,3R)-3-hydroxycyclopentyl)-1H-pyrazol-3-yl)-3-(methoxymethyl)-1-methyl-1H-pyrazole-5-carboxamide (compound A) (187 g, 0.586 mol) (prepared by acidic deprotection of intermediate 13B described in Example 13 of U.S. Pat. No. 11,014,911) was dissolved in tetrahydrofuran (THF) (1.78 L) with vigorous stirring using magnetic stirring. The solution was warmed to 25° C. and then 1,1′-carbonyldiimidazole (CDI) (142 g, 0.876 mol) was added. The mixture was stirred at 25° C. for 5 min, then warmed to 50° C. at 1° C. / min and held for 30 min. The mixture was cooled to 30° C. and then 2-propylamine (iPrNH2) (70 g, 1.184 mol) was charged. The reaction was warmed to 50° C. at 1° C. / min and then held at 50° C. until the reaction was complete. If necessary, additional iPrNH2 (18 g, 0.304 mol) was added to drive the reaction to completion. Water (1.22 L) was added and the mixture was warmed to 50° C. A solution of potassium hydroxide (20 g, 0.356 mol) in water (0.561 L) was added and the mixture was held at 50° C. for 5 hours. The reaction was cooled to 25° C. and the reaction mixture was distilled under vacuum until the solution volume was 6 mL / g based on compound A, the internal temperature was between 45-50° C. and THF was less than 0.1% by GCHS. The mixture was cooled to 25° C. and then H2O was added until the reaction volume was 16 mL / g based on compound A. Acetonitrile (0.75 L) was added via addition funnel and held for 10 min, then 37% hydrochloric acid in water (29 g) was added over 30 min to adjust the pH to between 7-8. Additional HCl or KOH was added to adjust the mixture to pH 7-8. The mixture was warmed to 40° C. and held for 3 h. The mixture was cooled to 15° C. at 0.1° C. / min and stirred at 15° C. for 1 h. The mixture was filtered and the solid was rinsed with 9:1 HO / acetonitrile (0.500 L). The solid was dried in a humidified vacuum oven at 50° C. until Karl Fischer (KF) titer was between 4.2% and 4.5% to give PF-07104091 monohydrate (Form 3).
[0325] [Table 4]
[0326] [Table 5]
[0327] [Table 6]
[0328] Example 4 Preparation of anhydrous crystalline PF-07104091 (Form 5)
[0329] [ka] Anhydrous crystalline PF-07104091 (Form 5) was prepared by placing PF-07104091 monohydrate (Form 3) in an open dish in an oven at approximately 50° C. and purging with dry nitrogen gas for approximately 3 hours.
[0330] Alternatively, anhydrous crystalline PF-07104091 (Form 5) was prepared by storing PF-07104091 monohydrate (Form 3) over a Drylite dessicant (approximately 0% RH) at ambient temperature for 17 days.
[0331] Elemental analysis of PF-07104091 (Form 5) was consistent with the anhydrate form, as shown in Table 7.
[0332] [Table 7]
[0333] As shown in FIG. 15, less than 1% weight loss at 200° C. was observed by thermogravimetric analysis for PF-07104091 (Form 5), confirming that the form is anhydrous.
[0334] [Table 8]
[0335] [Table 9]
[0336] [Table 10]
[0337] Example 5 Preparation of amorphous PF-07104091 (Form 4)
[0338] [ka] Amorphous PF-07104091 (Form 4) was prepared by in situ melt quenching of PF-07104091 monohydrate (Form 1) (prepared as described in U.S. Pat. No. 11,014,911) in a differential scanning calorimeter (DSC). Large-scale preparation of amorphous Form 4 was attempted using both melt quenching and freeze drying.
[0339] The general DSC procedure used to obtain amorphous PF-07104091 (Form 4) is provided below. 1. Weigh out 3-5 mg of API into an aluminum pan and seal it with an aluminum lid but do not seal it. 2. Load the pan into the DSC under a 50 L / min nitrogen gas purge. 3. Change temperature at 20°C / min to -30°C 4. Hold at isothermal temperature for 1 minute 5. Ramp at 10°C / min to 160°C 6. Hold at isothermal temperature for 1 minute 7. Change temperature at 20°C / min to -30°C 8. Hold at isothermal temperature for 1 minute 9. Ramp at 10°C / min to 160°C
[0340] A representative DSC thermogram is provided in FIG. 14 from the second heating cycle (i.e., step 9 above), which shows a glass transition temperature (T g ) (measured by DSC at a ramp rate of 10° C. / min) are shown.
[0341] Amorphous PF-07104091 (Form 4) has a PXRD pattern (2θ) containing broad peaks at diffraction angles (2θ) from about 5 to about 35° 2θ±0.2° 2θ, as shown in FIG. 4, without any of the sharp peaks characteristic of the crystalline forms.
[0342] Comparative Example 6 Crystalline PF-07104091 monohydrate (Form 1)
[0343] [ka]
[0344] PF-07104091 monohydrate (Form 1) was prepared as described in Example 13 of U.S. Pat. No. 11,014,911. PXRD, Raman and 13 C ssNMR characterization data is provided in Tables 11, 12 and 13, respectively.
[0345] [Table 11]
[0346] [Table 12]
[0347] [Table 13]
[0348] Example 7 stability studies Slurry experiments were performed as follows: The indicated starting form of PF-07104091 was transferred to a 2 mL vial. The indicated solvent or solvent mixture was added to obtain a slurry at the specified temperature (Table 14). Additional solids were added as necessary to ensure a sufficiently thick slurry. A magnetic stir bar was added and the vial was tightly capped to prevent solvent loss. The resulting slurry was allowed to stir at the specified temperature. Aliquots were removed from the slurry periodically or after a certain duration. The solids were separated from the liquid by centrifugal filtration and the solids were characterized by powder X-ray diffraction. PF-07104091 monohydrate (Form 3) was the thermodynamically most stable form at 4° C., approximately 25° C. (ambient) and 40° C.
[0349] [Table 14]
[0350] The single crystal x-ray structure of PF-07104091 monohydrate (Form 3) was determined and is shown in Figure 16. Computer analysis showed that PF-07104091 monohydrate (Form 3) has superior intermolecular shape, hydrogen bond network topology and lack of voids compared to PF-07104091 monohydrate (Form 1), and is therefore expected to be more stable. The single crystal x-ray structure of PF-07104091 monohydrate (Form 1) is provided in Figure 1 of US Patent No. 11,014,911.
Claims
1. A crystalline form of (1R,3S)-3-[3-({[3-(methoxymethyl)-1-methyl-1H-pyrazol-5-yl]carbonyl}amino)-1H-pyrazol-5-yl]cyclopentylpropan-2-ylcarbamate (PF-07104091) monohydrate (Form 3) having a powder X-ray diffraction (PXRD) pattern with peaks at 2θ values measured using CuKα radiation of 8.4, 10.1, and 21.5°2θ±0.2°2θ.
2. 2. The crystal of claim 1, having a PXRD pattern further comprising a peak at a 2θ value measured using CuKα radiation of 16.9°2θ±0.2°2θ.
3. 3. The crystal of claim 1 or 2, having a PXRD pattern further comprising a peak at a 2θ value measured using CuKα radiation of 27.0°2θ±0.2°2θ.
4. 1657, 1595 and 1408 cm -1 ±2cm -1 One, two or three wave numbers (cm -1 4. The crystal of claim 1 , having a Raman spectrum including a .alpha.-.alpha. value.
5. Contains one, two or three resonance (ppm) values selected from the group consisting of 25.2, 37.5 and 159.3 ppm ± 0.2 ppm. 13 The crystal according to any one of claims 1 to 4, having a C solid-state NMR spectrum.
6. Further including resonance (ppm) values of 151.9 and 152.5 ppm ± 0.2 ppm 13 The crystal according to claim 5, having a C solid-state NMR spectrum.
7. Includes resonance (ppm) values of 25.2, 37.5 and 159.3 ppm ± 0.2 ppm 13 Crystals of PF-07104091 monohydrate (Form 3) having a C solid-state NMR spectrum.
8. Further comprising one or two resonance (ppm) values selected from the group consisting of 151.9 and 152.5 ppm ± 0.2 ppm. 13 The crystal according to claim 7, having a C solid-state NMR spectrum.
9. 9. The crystal of claim 7 or 8, having a PXRD pattern including peaks at 2θ values measured using CuKα radiation of 8.4 and 10.1°2θ±0.2°2θ.
10. The crystal of any one of claims 1 to 9, which is substantially pure PF-07104091 monohydrate (form 3).
11. Anhydrous crystalline PF-07104091 (Form 2) having a PXRD pattern including peaks at 2θ values measured using CuKα radiation of 9.8, 13.3, and 17.4°2θ±0.2°2θ.
12. 12. The crystal of claim 11, having a PXRD pattern further comprising a peak at a 2θ value measured using CuKα radiation of 4.2°2θ±0.2°2θ.
13. 13. The crystal of claim 11 or 12, having a PXRD pattern further comprising a peak at a 2θ value measured using CuKα radiation of 7.5°2θ±0.2°2θ.
14. 1691, 1582 and 996 cm -1 ±2cm -1 One, two or three wave numbers (cm -1 14. The crystal of claim 11, having a Raman spectrum including a .alpha.-.alpha. value.
15. 1, 2 or 3 resonance (ppm) values selected from the group consisting of 24.1, 39.8 and 41.6 ppm ± 0.2 ppm 13 15. The crystal of any one of claims 11 to 14, having a C solid-state NMR spectrum.
16. Further including resonance (ppm) values of 21.8 and 138.2 ppm ± 0.2 ppm 13 The crystal of claim 15 having a C solid-state NMR spectrum.
17. 17. The crystal of any one of claims 11 to 16, which is substantially pure PF-07104091 (Form 2).
18. Anhydrous crystalline PF-07104091 (Form 5) having a PXRD pattern containing three or more peaks at 2θ values measured using CuKα radiation selected from the group consisting of 10.2, 12.4, 15.4, 17.2, 17.9, 19.8, 21.6, 22.5, 23.7 and 26.2 °2θ±0.2 °2θ.
19. An amorphous solid of PF-07104091 (Form 4) having a PXRD pattern including broad peaks at diffraction angles (2θ) measured using CuKα radiation from about 5 to about 35° 2θ±0.2° 2θ.
20. 20. The amorphous solid of claim 19, having essentially the same PXRD pattern as in FIG.
21. Glass transition temperature (T g 21. The amorphous solid of claim 19 or 20, having a molecular weight of 1:1 or more.
22. A pharmaceutical composition comprising a crystal described in any one of claims 1 to 18 or an amorphous solid described in any one of claims 19 to 21, and a pharma- ceutically acceptable carrier or excipient.
23. The pharmaceutical composition of claim 22 for use in treating cancer in a subject.
24. 24. The pharmaceutical composition of claim 23, wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, lung cancer, liver cancer, kidney cancer, bladder cancer, ovarian cancer, peritoneal cancer, fallopian tube cancer, cervical cancer, uterine cancer, pancreatic cancer, gastric cancer, colorectal cancer, esophageal cancer, head and neck cancer, testicular cancer, adrenal cancer, skin cancer, brain tumor, sarcoma and lymphoma.
25. A pharmaceutical composition described in claim 23 or 24 for use in combination with an additional anticancer agent.
